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The practice of biological chemistry in the post-genomic era has included increasingly 
broad and detailed interrogation of cellular processes at the molecular level. In 
particular, enzymology has been equipped with a wide range of physical and analytical 
tools to study in detail chemical reactions catalyzed by enzymes. 
The present work describes studies aimed at characterizing enzymes involved in 
bacterial metabolism. First, a pre-steady-state kinetic analysis is described of CysM, a 
cysteine synthase from Mycobacterium tuberculosis. This analysis led to two principal 
results. O-phospho-L-serine was identified as the immediate biosynthetic precursor for 
cysteine in its CysM-mediated biosynthesis in M. tuberculosis. The substrate for 
CysM and related enzymes in bacteria was previously assumed to be O-acetyl-L-
serine. The study also resulted in the first detailed pre-steady-state kinetic 
characterization of sulfur transfer from a small sulfur carrier protein (CysO) to an 
enzyme-bound intermediate in a biosynthetic pathway. 
The second study involved biochemical characterization of the HpxO enzyme from 
Klebsiella pneumoniae. This enzyme catalyzes the oxidation of uric acid to 5-
hydroxyisourate as part of the purine catabolic pathway. The activity of HpxO was 
shown to depend on flavin adenine dinucleotide (FAD), in contrast to all previously-
studied urate oxidase enzymes, which employ a cofactor-independent chemical 
 mechanism. The results confirmed the existence of a novel mechanistic paradigm in 
purine catabolism. A series of HpxO active-site mutants were generated and 
characterized kinetically in order to gain further insight into the HpxO-catalyzed 
mechanism of urate hydroxylation, in the context of its X-ray crystal structure. 
The third study reported here involved characterization of a biosynthetic pathway for 
bacimethrin, a thiamin antimetabolite. We identified a previously unknown 
biosynthetic pathway for bacimethrin in Clostridium botulinum and reconstituted in 
vitro the three enzymatic activities which are responsible for conversion of cytidine 
monophosphate to bacimethrin. We also investigated the activity of a thiaminase I 
enzyme found in the C. botulinum bacimethrin biosynthetic cluster. Our results 
implicate thiaminase I as a potentiator of bacimethrin toxicity and indicate a possible 
role for this enzyme in extracellular salvage of thiazole for thiamin biosynthesis. 
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CHAPTER 1 
Pre-steady-state kinetic studies on CysM, a cysteine synthase from 
Mycobacterium tuberculosis with novel substrate specificity.1 
 
1.1. Introduction. 
Mycobacterium tuberculosis is a widespread and dangerous pathogen which exerts 
significant deleterious effects on humans both from health and economic standpoints 
(1). An understanding of the metabolism of this bacterium is clearly advantageous in 
order to establish means for its control and treatment of the symptoms which infection 
produces in humans. This is particularly the case where the possibility of discovering 
new metabolic pathways specific to M. tuberculosis exists, as these may be exploited 
by the development of therapeutic agents. 
The biosynthesis of L-cysteine is thought to occur via at least four pathways (Figure 
1.1). The first of these was reported by Kredich and Tompkins and involves two 
enzymatic steps (2) beginning with L-serine. The first step is activation as a leaving 
group of the serine hydroxyl by acetylation, catalyzed by the acetyl-CoA-dependent 
enzyme serine acetyltransferase (3). O-acetyl-L-serine then undergoes a β-replacement 
reaction catalyzed by a PLP-dependent cysteine synthase. In Salmonella typhimurium 
bisulfide (HS-) has been shown to be a nucleophilic substrate for the β-replacement  
 
______________________________ 
1Reproduced with permission from O’Leary, S. E., Jurgenson, C. T., Ealick, S. E., 
Begley, T. P. (2008) O-Phospho-L-serine and the thiocarboxylated sulfur carrier 
protein CysO-COSH are substrates for CysM, a cysteine synthase from 
Mycobacterium tuberculosis, Biochemistry 47, 11606–11615. Copyright 2008, 
American Chemical Society. 
1 
reaction, and the kinetics of the S. typhimurium enzyme have been studied extensively. 
These studies have been reviewed by Tai and Cook (4).  
A variation on this pathway has been identified in the hyperthermophilic archaeon 
Aeropyrum pernix, where O-phospho-L-serine is the immediate biosynthetic precursor 
for L-cysteine (5, 6). The catabolism of L-cystathionine by L-cystathionine γ-lyase to 
produce L-cysteine, 2-oxobutyrate and ammonia is thought to be the predominant 
biosynthetic route for cysteine in eukaryotic and mammalian systems but also has 
been shown to take place in some bacteria (7). A fourth pathway in the methanogenic 
archaea was recently described which is tRNA-dependent and proceeds via an O-
phosphoseryl-tRNACys intermediate which can be converted to cysteinyl-tRNACys and 
thence to cysteine (8). 
 
 
Figure 1.1. Biosynthetic pathways for L-cysteine. 
 
2 
Inspection of the sequenced M. tuberculosis H37Rv genome reveals the presence of 
four loci assigned as coding for cysteine synthase enzymes. Locus Rv2334, coding for 
the cysK gene is contiguous with locus Rv2335 (cysE), proposed to code for serine 
acetyltransferase. A second open reading frame (Rv0848) contains the cysK1 gene but 
no serine acetyltransferase is present. Locus Rv3684 is also proposed to code for a 
cysteine synthase gene, but is also not clustered with the serine acetyltransferase, 
instead being neighbored by regions coding for a proposed phosphohydrolase enzyme 
(Rv3683) and prolyl tRNA (Rvnt40). The fourth and final open reading frame, 
Rv1336, codes for a cysteine synthase (CysM) which is found clustered with, amongst 
others, a gene coding for a small sulfur carrier protein (CysO). 
Previous work from our laboratory reported the reconstitution of a new cysteine 
biosynthetic pathway in M. tuberculosis (9) which involves CysM. This enzyme has 
extensive sequence homology to the O-acetylserine sulfhydrylases and is predicted on 
this basis to belong to the O-acetylserine sulfhydrylase B family of enzymes. The new 
pathway utilizes the 93-amino acid sulfur carrier protein (CysO), which clusters with 
CysM in the M. tuberculosis H37Rv genome. Similar sulfur carrier proteins have been 
identified in the biosynthetic pathways for thiamin (10) and molybdopterin (11) and 
quinolobactin (12, 13). These proteins also show homology to components of the 
system which targets doomed proteins by ubiquitination for degradation by the 
proteasome (14). A key feature of these proteins is a flexible C-terminal Gly-Gly tail 
which can insert into the active site of their partner enzymes to facilitate sulfur 
transfer. It has been shown that to form the C-terminal thiocarboxylate, the proteins 
are first activated by adenylation of their C-termini and then undergo nucleophilic 
addition-elimination chemistry with a sulfide equivalent, the production of which 
involves enzymes such as cysteine desulfurases or rhodanese homology domain 
proteins. The M. tuberculosis moeZ (Rv3206) gene product (15) contains such a 
3 
rhodanese homology domain as well as a ThiF-like domain and was shown to catalyze 
the formation of the CysO thiocarboxylate using an unidentified sulfur source in cell-
free extract. ThiF is the enzyme responsible for the adenylation of ThiS-COOH in the 
thiamin biosynthetic pathway in prokaryotes (16). The expression of MoeZ is 
upregulated under the same conditions that produce upregulation of CysO and CysM 
expression. A zinc-dependent hydrolase Mec+ (17) was shown to catalyze the selective 
hydrolysis of the CysO-cysteine adduct formed after attack of thiocarboxylated CysO 
(CysO-COSH) at the α-aminoacrylate intermediate formed at the CysM active site. 
The mec+ gene (Rv1334) clusters with the cysO and cysM genes. 
 
Figure 1.2. Proposed catalytic mechanism for CysM, based on studies on the related 
O-acetylserine sulfhydrylase family of PLP-dependent β-replacement enzymes. 
4 
Given that no acetyltransferase gene is found clustered with the cysM and cysO genes, 
there is no reason to assume a priori that O-acetyl-L-serine is the physiological amino 
acid substrate for CysM. In order to test this hypothesis, and to investigate the reaction 
of CysO-COSH as the nucleophilic substrate for CysM, we have characterized the 
CysM kinetic pathway under transient-state and single-turnover conditions using both 
O-acetyl- and O-phospho-L-serine as the amino acid substrates and CysO-COSH and 
bisulfide as the nucleophilic substrates. The proposed chemical mechanism for CysM 
is shown in Figure 1.2. In brief, this mechanism involves formation of an imine (1.4) 
between CysM-bound pyridoxal 5′-phosphate and the amino acid substrate via a 
transient geminal diamine intermediate (1.3), followed by elimination across the α,β 
bond of the substrate to form a relatively stable α-aminoacrylate intermediate (1.5). 
1,4-Addition of a suitable nucleophile such as CysO-COSH to this intermediate 
affords the β-substituted amino acid imine (1.6), which undergoes transimination with 
an active site lysine residue to release the product (1.8) and regenerate the active site 
for catalysis. 
 
1.2. Results. 
1.2.1. Formation of the a-aminoacrylate from O-acetyl-L-serine. 
The aminoacrylate intermediate could be formed from O-acetyl-L-serine (Figure 1.3A) 
and the increase in absorbance at 465 nm due to its formation on treatment of CysM 
with OAS could be best fit using a single exponential function at each of the various 
concentrations of OAS employed, to give the first order rate constants for formation. 
The dependence of these rate constants on the OAS concentration was best described 
by a hyperbolic function. A dissociation constant (Kd = 1/K1) for OAS of 5 ± 2 mM 
and a first order rate constant of 0.025 ± 0.004 s-1 were determined for formation of 
the aminoacrylate intermediate. This intermediate was stable for more than 30 minutes  
5 
Figure 1.3. Ultraviolet-visible spectroscopy of formation of the CysM-bound α-
aminoacrylate intermediate. (A) Mixing of CysM (14 μM) with O-acetyl-L-serine (5 
mM) produces a decrease in the absorbance due to enzyme-bound pyridoxal-5′-
phosphate (1.1) at 412 nm and an increase in the absorbance at 458 nm due to the 
formation of an α-aminoacrylate intermediate (1.5). The traces were recorded at 
intervals of approximately 34 s after mixing, in 50 mM Tris-HCl, pH 8.0 and at room 
temperature. (B) Absorbance changes due to mixing of O-phospho-L-serine (10 μM) 
with CysM (14 μM) in 50 mM Tris-HCl at pH 8.0 and at room temperature. Individual 
traces were recorded at intervals of approximately 30 s. The changes reflect 
conversion of the enzyme-bound PLP imine (1.1, λmax = ~412 nm) to a stable α-
aminoacrylate intermediate (1.5, λmax = ~462 nm). 
 
(data not shown). Additionally, the hyperbolic function was found to pass through the 
origin. The limiting initial slope of the hyperbola, determined as kmax/Kd provides an 
estimate of the second order rate constant for formation of the aminoacrylate 
intermediate, and was found to be 0.005 ± 0.002 mM-1 s-1. This estimate is model-
dependent and applies only in the case of rapid-equilibrium binding followed by a 
single rate-limiting step, consistent with the proposed chemical mechanism. No 
6 
evidence for reversibility of the formation of the aminoacrylate was found under the 
conditions of its formation. 
 
1.2.2. Formation of the a-aminoacrylate from O-phospho-L-serine 
The α-aminoacrylate intermediate could also be formed from O-phospho-L-serine 
(Figure 1.3B)  and the increase in absorbance at 465 nm due to its formation on 
treatment of CysM with OPS could also be fit using a single exponential function at 
the various concentrations of OPS examined (Figure 1.4). The data for this substrate 
was treated as described for O-acetyl-L-serine to give a first order rate constant of 17 ± 
2 s-1 for formation of the aminoacrylate and a Kd of 6 ± 1 mM. The second order rate 
constant for formation of the aminoacrylate intermediate was thus estimated at 2.8 ± 
0.7 mM-1 s-1. The intermediate could be partially quenched by addition of high 
concentrations of potassium phosphate (> 10 mM, data not shown). 
 
1.2.3. Formation and decay of the a-aminoacrylate with L-cysteine. 
When CysM was treated with L-cysteine, an increase in the absorbance at 465 nm was 
detected consistent with formation of the α-aminoacrylate intermediate. However, this 
was found to subsequently decay on a longer timescale. The resulting traces at the 
various concentrations of L-cysteine examined were best fit by double exponential 
functions to give two sets of first order rate constants at the various cysteine 
concentrations, one for formation and one for decay of the aminoacrylate intermediate 
(Figure 1.5). The first order rate constants for formation of the aminoacrylate were 
plotted as a function of the concentration of L-cysteine and the resulting data were best 
fit by a line with a slope of 0.0044 ± 0.0004 mM-1 s-1. The rate of decay of the 
aminoacrylate intermediate was independent of the concentration of L-cysteine within 
experimental error, being of the order of 0.001 s-1 (data not shown). 
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Figure 1.4. Kinetics of formation of α-aminoacrylate intermediate from O-phospho-L-
serine. (A) Changes in absorbance at 465 nm following rapid mixing of O-phospho-L-
serine (OPS; 0.5, 1, 2, 5 and 10 mM in order of increasing rate) with CysM (4.5 μM) 
in 50 mM Tris-HCl at pH 8 and at ~22 °C. The resulting data were fit to single 
exponential functions to give the first order rates at the various concentrations of O-
phospho-L-serine. (B) Plot of the rates of acrylate formation as a function of O-
phospho-L-serine concentration, fit to a hyperbolic function describing a rapid 
equilibrium binding model. From this fit, the Kd for OPS was found to be 6 ± 1 mM 
and the second order rate constant for formation of the aminoacrylate intermediate was 
2.8 ± 0.7 mM-1 s-1. 
8 
  
Figure 1.5. Kinetics of formation and decay of the α-aminoacrylate intermediate in 
the presence of cysteine. (A) CysM (31 μM) was mixed with cysteine (1, 4 and 8 mM 
in order of increasing rate) in 50 mM Tris-HCl, pH 8.0 and at ~22 °C and the change 
in absorbance at 465 nm was monitored. The data are shown fit to functions of the 
form y = Ae-kt + Be-kt + C. (B) Dependence of the rate of formation of the 
aminoacrylate intermediate on the concentration of cysteine. The slope of the line 
fitting the data is a measure of the specificity of the enzyme for this amino acid 
substrate and was found to be 0.0044 ± 0.0004 mM-1 s-1. The rate of decay of the 
aminoacrylate intermediate was independent of the concentration of L-cysteine within 
experimental error, being of the order of 0.001 s-1. 
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1.2.4. Quenching of the α-aminoacrylate intermediate by bisulfide. 
The α-aminoacrylate intermediate was pre-formed under single turnover conditions by 
treatment of CysM (25 μM) with O-phospho-L-serine (20 μM) in 50 mM Tris-HCl at 
pH 8. Addition of sodium sulfide (0.1 – 15 mM final bisulfide concentration) caused a 
decrease in the absorbance at 465 nm (Figure 1.6). This decrease was fit to a single 
exponential function to give the observed rates for decay at the various bisulfide 
concentrations employed. The rate constants exhibited the hyperbolic dependence on 
the concentration of bisulfide consistent with a rapid-equilibrium binding model, with 
a predicted rate constant for quenching of 0.48 ± 0.07 s-1 and a Kd for bisulfide of 7 ± 
2 mM, yielding an apparent second order rate constant for quenching of 0.07 ± 0.02 
mM-1 s-1. 
 
1.2.5. Quenching of the α-aminoacrylate intermediate by CysO-COSH.  
Addition by rapid mixing of a solution of CysO-COSH to a pre-formed solution of the 
α-aminoacrylate under single turnover conditions also caused a decay in the 
absorbance at 465 nm (Figure 1.7). This decay could be fit to a single exponential 
function to give the observed rate for decay at the various concentrations of CysO-
COSH examined. The rate of reaction of CysO-COSH with the CysM-bound 
aminoacrylate intermediate could not be saturated at the highest available CysO-
COSH concentration (250 μM), which approached the solubility limit for the protein. 
We therefore restricted our analysis to the reaction of CysO-COSH in the 0–125 μM 
concentration range. A comparison of the specificity of CysM for the nucleophilic 
substrates, which was the aim of the present study, is readily obtained from such an 
analysis. The data describing the dependence of the rate of reaction of CysO-COSH in 
this concentration range with the CysM-bound aminoacrylate intermediate fit well to a 
line with a slope of 88 ± 6 mM-1 s-1. This value can be interpreted as an estimate of the 
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second order rate constant for the reaction (Figure 5). The y-intercept of this line had a 
value of 0.61 ± 0.43 s-1. 
Figure 1.6. Kinetics of quenching of the α-aminoacrylate intermediate by bisulfide. 
The CysM/O-phospho-L-serine α-aminoacrylate intermediate was pre-formed by 
mixing CysM with a stoichiometric quantity of O-phospho-L-serine in 50 mM Tris-
HCl, pH 8.0 at room temperature (~22 °C), then mixed with a solution of sodium 
sulfide in the same buffer. (A) Representative trace with exponential fit showing decay 
of absorbance at 465 nm after rapid mixing of the pre-formed CysM/O-phospho-L-
serine α-aminoacrylate intermediate (11 μM) with sodium sulfide (0.5 mM). (B) 
Dependence of the rate of reaction on the bisulfide concentration (0.1 – 15 mM), fit to 
a hyperbolic function, The Kd for bisulfide was found to be 7 ± 2 mM and the first 
order rate constant for the carbon-sulfur bond-forming addition reaction was 0.48 ± 
0.07 s-1. 
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Figure 1.7. Kinetics of quenching of the α-aminoacrylate intermediate by CysO-
COSH. The CysM/O-phospho-L-serine α-aminoacrylate intermediate was pre-formed 
by mixing CysM (14 μM) with O-phospho-L-serine (11 μM) in 50 mM Tris-HCl, pH 
8.0 at room temperature (~22 °C). This solution was then rapidly mixed with a 
solution containing CysO-COSH in the same buffer. (A) Representative trace with 
exponential fit showing decay of absorbance at 465 nm after rapid mixing of the 
CysM/O-phospho-L-serine α-aminoacrylate intermediate with CysO-COSH (0.05 
mM) in 50 mM Tris-HCl at pH 8 and at room temperature. (B) Plot of the first-order 
rates of decay at the various CysO-COSH concentrations with a linear fit. The slope of 
this line is a measure of the specificity of the enzyme for this nucleophilic substrate 
and was found to be 88 ± 6 mM-1 s-1. 
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1.3. Discussion. 
1.3.1. Kinetic scheme for CysM.  
The minimal kinetic scheme for CysM (Figure 1.8) can be derived from the full 
pathway (Figure 1.2) by its collapse due to the kinetic silence of the geminal diamine 
intermediates (3 and 7) and the aldimine intermediate 1.4.. There was neither a lag in 
formation of the observable α-aminoacrylate intermediate, nor a dependence of the 
amplitude for aminoacrylate formation on the substrate concentration, suggesting that 
the forward partitioning of all intermediates up to and including the imine 1.4 must be, 
respectively, rapid and favorable. Indeed in the case of the cysteine synthase OASS-A 
from Salmonella typhimurium LT-2, the CysM-bound PLP-OAS aldimine 
intermediate (equivalent to structure 1.4) could only be observed on a low millisecond 
timescale and a precise rate for its formation was not reported (22). The kinetic 
pathway of CysM thus resembles that reported for the O-acetylserine sulfhydrylase 
enzymes with respect to the “elimination” half-reaction which generates the 
aminoacrylate intermediate. However, in the second CysM half-reaction a hitherto 
unexplored mechanistic variation presents itself in the form of CysO-COSH, which 
acts as a sulfide equivalent. Additionally, this half-reaction of CysM offered a more 
detailed insight than had been previously available in any system into the kinetics of 
sulfur transfer mediated by CysO-like proteins. The biosynthetic enzymes for thiamin 
(23) and quinolobactin (12) are experimentally much less tractable with regard to 
making detailed kinetic measurements on the sulfur transfer reaction. 
 
1.3.2. Formation of the α-aminoacrylate intermediate. 
Mixing of CysM with an excess of O-acetyl-L-serine or O-phospho-L-serine (Figure 
1A and 1B, respectively) produces initially a red shift of the absorbance at 412 nm due  
13 
 Figure 1.8. Minimal kinetic model for CysM. 
 
to the enzyme-PLP internal aldimine (1.1). This is consistent with the data observed 
for reaction of the previously-studied O-acetylserine sulfhydrylase A enzyme from 
Salmonella typhimurium with OAS, and is attributed to the transient formation of the 
enzyme-PLP external aldimine (1.4), which then rapidly converts to the aminoacrylate 
intermediate. The lack of an isosbestic point in the data obtained with CysM contrasts 
with the situation for the reaction of OAS with the B-isozyme from S. typhimurium 
(24). 
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The kinetics of formation of the aminoacrylate may be described in terms of a rapid 
equilibrium binding model (Figure 1.8) where the rate of dissociation of the ES 
complex, k-1, is much greater than the rate of the subsequent, kinetically significant, 
chemical step, i.e. the β-elimination reaction (k2). This model has been used 
previously to describe the formation of the aminoacrylate intermediate from OAS, 
catalyzed by O-acetylserine sulfhydrylase enzymes from Salmonella typhimurium and 
Escherichia coli, and predicts a hyperbolic dependence of the observed rate constant 
for chemistry on the substrate concentration, with saturation of the rate of the chemical 
step at concentrations of substrate which saturate the ES complex. In this model, an 
aminoacrylate intermediate at a CysM active site under conditions of zero substrate 
concentration may only undergo reverse reaction. Hence, the y-intercept of such a 
hyperbola corresponds to the back-rate for the chemical reaction (k-2). Equation (2) 
also defines the equilibrium constant K1 for substrate association, which is the 
reciprocal of the dissociation constant (Kd) The quotient K1[S]/(K1[S] + 1) is a fraction 
that ranges from 0 to 1, reflecting the formation of the ES complex. The rates of 
formation of the aminoacrylate intermediate in a single turnover from both O-acetyl- 
and O-phospho-L-serine were found to exhibit hyperbolic dependence on the substrate 
concentrations, consistent with this model. Both substrates have comparable 
dissociation constants (Kd) of 6 mM (OPS) and 5 mM (OAS). The Michaelis constants 
(Km) for these amino acids with respect to enzymes which utilize them as substrates 
appear to be, broadly speaking, in the mid-micromolar to low millimolar range (25, 
26). The relatively high dissociation constants for the amino acid substrates are similar 
to that determined for OAS in studies on the O-acetylserine sulfhydrylase A enzyme 
from Salmonella typhimurium. However, the rates of the elimination reaction to form 
the aminoacrylate intermediate were found to vary substantially between O-acetyl- 
and O-phospho-L-serine. The rate of the β-elimination reaction of acetic acid to give 
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the aminoacrylate intermediate (0.025 s-1) is 850-fold slower than that of the 
elimination of, formally, [HPO4]2- (17 s-1), suggesting the presence of stabilizing 
interactions at the CysM active site which facilitate such a rate enhancement. 
In the case of OAS, the apparent second order rate constant for formation of the 
aminoacrylate was found to be 0.005 mM-1 s-1, compared with 2.8 mM-1 s-1 for O-
phospho-L-serine. This 560-fold specificity suggests that O-phospho-L-serine and not 
O-acetyl-L-serine is the physiologically relevant substrate for CysM. Given the 
similarity of the dissociation constants for both substrates, the ultimate origin of this 
specificity appears to be the chemical reactivity of OPS at the CysM active site. 
In order to further evaluate the plausibility of OPS as a substrate for CysM, we 
investigated the CysM-catalyzed reaction of cysteine. It would seem logical that 
physiologically-relevant substrates for cysteine synthases must greatly out-compete 
the intrinsic cysteine synthase-catalyzed reactivity of cysteine itself. Cysteine reacts 
with biphasic kinetics in the presence of CysM as it both forms and quenches the 
aminoacrylate intermediate. In the case of OASS-A from Salmonella typhimurium, the 
quenching reaction has been reported to form a thioether product (27). The time 
course of reaction of cysteine with CysM is thus described by a double exponential 
function with the first and second phases resulting from the formation and quenching 
of the aminoacrylate, respectively (Figure 1.5). The formation of the aminoacrylate 
from cysteine also exhibits rapid-equilibrium binding kinetics, with the apparent 
second order rate constant (0.0044 mM-1 s-1) suggesting that L-cysteine itself is an 
equally-good substrate for CysM as OAS. Such an observation points strongly to OPS 
as a more likely substrate for CysM than OAS. This contrasts with the situation for the 
previously-studied OASS-B from Salmonella typhimurium, which does not utilize 
OPS as a substrate (28). 
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1.3.3. Quenching of the α-aminoacrylate intermediate.  
The reaction of the CysM-bound α-aminoacrylate intermediate in the carbon-sulfur 
bond-forming conjugate addition constitutes the second half-reaction characteristic of 
cysteine synthases. In all previously-studied systems bisulfide is the sulfur donor. 
CysM offers a hitherto unexplored mechanistic variation on the existing paradigm in 
the form of CysO-COSH, the thiocarboxylated sulfide carrier protein which acts as a 
sulfide source for this second half reaction. Additionally, the CysM system allowed 
kinetic characterization of the sulfide transfer event mediated by CysO-COSH. This 
characterization has not been possible for any of the other sulfide carrier proteins. To 
characterize this second half-reaction of CysM we examined the reaction of the pre-
formed aminoacrylate intermediate with both CysO-COSH and bisulfide. 
The aminoacrylate intermediate could be quenched by bisulfide to give L-cysteine. 
The dependence of the observed rate for quenching on the concentration of bisulfide 
was hyperbolic, also consistent with a rapid-equilibrium binding model. From the 
hyperbolic fit to the data, the rate constant k5 for quenching of the aminoacrylate by 
bisulfide was found to be 0.48 s-1, with a Kd for bisulfide of 7 mM. This value suggests 
that appreciable binding of bisulfide to CysM should occur only at a bisulfide 
concentration generally regarded as toxic to M. tuberculosis (29).  In contrast, the rate 
of quenching of the aminoacrylate in the presence of CysO-COSH depended linearly 
on the CysO-COSH concentration in the 0–125 μM range. The rate of quenching of 
the aminoacrylate by CysO-COSH could not be fully saturated at a CysO-COSH 
concentration of 250 μM, which approaches the solubility limit of the protein. The 
kinetic difference between CysO-COSH and bisulfide as nucleophiles provides an 
insight into the physical processes involved with the two sulfur sources. The 
quenching of the aminoacrylate by CysO-COSH requires association of the two 
proteins, likely followed by conformational changes in one or both proteins to place 
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the Gly-Gly-SH C-terminal sulfur atom of CysO-COSH in a position optimal for β-
addition to the aminoacrylate intermediate (1.5). It is not surprising that these steps 
should be slower than the subsequent chemical reaction. The slope of the line 
describing the concentration dependence of the quenching rate (88 mM-1 s-1) may thus 
be regarded as an estimate of the second order rate constant k4 for binding of CysO-
COSH to CysM. This is three orders of magnitude greater than the value of k5/Kd for 
bisulfide, computed for that substrate to be 0.07 mM-1 s-1, and which is an estimate of 
the specificity of the enzyme for this substrate. Comparison of these values strongly 
suggests that CysO-COSH is the nucleophilic substrate in vivo. The CysM active site 
with the aminoacrylate intermediate present cannot be readily accessible to the bulk 
solvent in the absence of CysO, as demonstrated by the longevity of the aminoacrylate 
even under conditions of exposure to nucleophiles such as cysteine, and its slow rate 
of reaction with bisulfide. In the case of OASS-A from Salmonella typhimurium, the 
rate of the β-addition reaction is thought to be diffusion-limited when bisulfide is the 
nucleophilic substrate (30). Therefore it is likely that binding of CysO causes a 
conformational change in CysM which facilitates the nucleophilic addition.  
The y-intercept of the linear fit describing the concentration-dependence of the rate of 
quenching of the OPS-derived CysM-aminoacrylate intermediate by CysO-COSH is 
nonzero and has a value of 0.61 ± 0.43 s-1, which is likely to estimate the rate of the 
rate-limiting step for back-reaction of the S-CysO-Cys external aldimine (1.6), i.e. re-
formation of the aminoacrylate and CysO-COSH. 
 
 
1.3.4. Role of CysM and CysO-COSH.  
Formation of the CysO-COSH thiocarboxylate represents a considerable energy 
investment for M. tuberculosis, with the direct involvement of at least two nucleoside 
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triphosphate molecules required to produce O-phospho-L-serine and activate CysO for 
formation of the C-terminal thiocarboxylate. The underlying reasons justifying this 
investment are not clear, but it is possible that the thiocarboxylate moiety represents a 
stable, oxidation-resistant and relatively non-toxic source of sulfide from which 
cysteine can be produced in the highly oxidizing environment of the macrophage. 
Inhibitors of CysM may thus have potential as antimycobacterial chemotherapeutic 
agents. 
 
1.4. Conclusions. 
A new cysteine biosynthetic pathway, in Mycobacterium tuberculosis, involving a 
sulfide carrier protein (CysO) and a cysteine synthase (CysM) has previously been 
described. Here we report the kinetic characterization of this system and determine 
that O-phospho-L-serine rather than O-acetyl-L-serine is the cosubstrate. The chemical 
mechanism of CysM involves formation of an α-aminoacrylate intermediate 
consistent with its assignment as a member of the PLP-dependent β-replacement 
family of enzymes. O-acetyl-L-serine has a comparable Kd to that of O-phospho-L-
serine, but the elimination of acetic acid is substantially slower than that of [HPO4]2-, 
resulting in a much smaller apparent second order rate constant for formation of the 
aminoacrylate intermediate. This appears to be analogous to the situation described for 
the hyperthermophilic archaeon Aeropyrum pernix K1, which has been shown to 
possess a cysteine synthase enzyme which selectively catalyzes the O-phosphoserine 
sulfhydrylation reaction (6). Our data show that the thiocarboxylated sulfur carrier 
protein (CysO-COSH) is likely to serve as the endogenous nucleophilic substrate in M. 
tuberculosis, having an apparent second order rate constant for quenching of the 
aminoacrylate intermediate that is more than 1200 times faster than bisulfide, the 
nucleophilic substrate assigned for homologous bacterial cysteine synthases. The 
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underlying reasons for involvement of a sulfur carrier protein in this pathway remain 
unclear. One possibility is that the oxidation-resistance of the thiocarboxylate moiety 
may be a important key factor in protecting sulfide from oxidation in the macrophage. 
 
1.5. Experimental. 
All reagents and chemicals were of the highest purity commercially available. Sodium 
sulfide (90 % dry, balance water) was obtained from Acros Organics. Stopped-flow 
experiments were performed using a KinTek stopped-flow spectrophotometer (KinTek 
Corporation). All reactions were carried out in 50 mM Tris-HCl at pH 8. Protein 
concentrations were determined by the method of Bradford (18) and the 
concentrations thus-determined for CysM were in agreement with those calculated 
from the absorbance (19) of the enzyme-PLP internal imine (1.1, ε412 = 7600 M-1 cm-1) 
and the α-aminoacrylate intermediate (1.5, ε465 ~ 9800 M-1 cm-1). 
 
1.5.1. Overexpression and purification of proteins. 
CysM was overexpressed in Escherichia coli BL21(DE3) using a pET16b vector and 
purified by nickel affinity chromatography. The thiocarboxylated sulfur carrier protein 
CysO-COSH was overexpressed as a fusion with an intein protein possessing a chitin 
binding domain using a modification of the method of Kinsland et al. (20). The cysO 
gene was expressed in pTYB1 in E. coli grown at 24 °C. The protein was purified 
using chitin affinity chromatography. The C-terminal thiocarboxylate was generated 
by soaking the chitin resin-bound protein obtained from clarified cell lysate in a 
cleavage buffer containing 25 mM (NH4)2S, 50 mM NaCl and 1 mM EDTA at pH 8 
and at 4 °C for 40 h before elution. All proteins were buffer-exchanged into 50 mM 
Tris-HCl, pH 8 and concentrated prior to use. 
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1.5.2. Data analysis.  
Single-wavelength stopped-flow data for formation and decay of the α-aminoacrylate 
were fit to exponential functions with the general form of equation (1.1): 
 
          (1.1) ∑ −∞ ±= kit eAAA
i
ti
 
where At is the absorbance at time t, A∞ is the absorbance at time ∞, Ai is the amplitude 
of the ith transient and ki is the phenomenological observed first order rate constant 
(kobs) for the ith transient. The data for formation and quenching of the α-
aminoacrylate intermediate which showed a hyperbolic dependence of the 
phenomenological first order rate constants for formation on the concentration of 
substrates were fit to equation (2) which describes a rapid equilibrium binding model. 
Details of this model are treated in the discussion. The kinetic and thermodynamic 
constants K1 = 1/Kd, k2 and k-2 are defined in Scheme 2. [S] is the substrate 
concentration. 
 
           (1.2) 212 1][
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Linear data for dependence of the first order rate constants for decay of the 
aminoacrylate were fit to equation (3): 
 
               kobs = kqapp[S] + kb           (1.3) 
 
where kqapp is the apparent second order rate constant for quenching and kb is a 
complex function of mechanistic rate constants contributing to re-formation of the 
aminoacrylate. Linear data for formation of the aminoacrylate were fit to equation (4): 
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                   kobs = kfapp[S] + kc    (1.4) 
 
where kfapp is the apparent second order rate constant for quenching and kc is a 
complex function of mechanistic rate constants contributing to the reverse reaction. 
 
1.5.3. Ultraviolet-visible spectroscopy of formation of the α-aminoacrylate 
intermediate. 
CysM (0.76 mg/mL) was treated with excess O-acetyl-L-serine (5 mM) in 50 mM Tris 
at pH 8 and at room temperature. Absorbance spectra in the region 300 – 550 nm were 
taken manually at intervals of approximately 34 s until no further change in the spectra 
was observed. In the case of O-phospho-L-serine, the enzyme (14 μM) was mixed with 
OPS (10 μM) and the absorbance spectra were recorded in the 380-500 nm region, 
with individual traces recorded at intervals of approximately 30 s. 
 
1.5.4. Single-wavelength kinetics of formation of the α-aminoacrylate intermediate. 
The instrumentation used varied with the timescale for aminoacrylate formation. 
Solutions of O-acetyl-L-serine were prepared freshly immediately before each 
experiment. All concentrations are final after mixing. In the case of O-acetyl-L-serine, 
CysM (20 μM) was treated with solutions of O-acetyl-L-serine (500 μM – 10 mM). 
The absorbance at 465 nm was recorded for 900 s after mixing. The concentration of 
OAS was not corrected for its first order conversion to N-acetyl-L-serine, which occurs 
at ~1% min-1 (21). The reaction conditions to form the aminoacrylate intermediate 
were still pseudo-first-order in OAS even taking a conversion of ~15% to N-acetyl-l-
serine into account. No evidence suggesting inhibition of formation of the 
aminoacrylate intermediate by N-acetyl-L-serine was observed. The absorbance as a 
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function of time after mixing was fit in each case to a single exponential function to 
give the rates of formation of the aminoacrylate intermediate at the various 
concentrations of OAS. These rates were plotted as a function of the concentration of 
OAS and the resulting data were fit to a hyperbolic function. In the case of O-
phospho-L-serine, where formation of the aminoacrylate intermediate was found to 
occur on a much faster timescale, the mixing was carried out using a stopped-flow 
device. CysM (4.5 μM) was rapidly mixed with OPS (1 mM – 10 mM) and the 
absorbance at 465 nm was recorded after mixing. The data from this experiment were 
analyzed as described above for OAS. 
 
1.5.5. Single-wavelength kinetics of formation and decay of the α-aminoacrylate 
intermediate with L-cysteine.  
CysM (31 μM) was treated with L-cysteine (1 mM – 10 mM). The absorbance at 465 
nm was monitored as a function of time (900 s) after mixing. The resulting trace 
showed an increase and subsequent decrease in absorbance over the course of the 
experiment and this was best fit to a double exponential to obtain the two first order 
rate constants for formation and decay of the absorbance at 465 nm. These were 
plotted as a function of L-cysteine concentration and in the case of both sets of rate 
constants fitted to linear functions. 
 
1.5.6. Effect of phosphate on the α-aminoacrylate intermediate. 
 CysM (19 μM), in 50 mM Tris-HCl at pH 8 was treated with potassium phosphate 
(10 mM – 100 mM) prepared from a 1.0 M stock solution, the pH of which was 
adjusted to 8 before dilution. 
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1.5.7. Single-wavelength kinetics of quenching of the α-aminoacrylate intermediate.  
The instrumentation in this case also varied with the nucleophilic substrate. In both the 
case of CysO-COSH and sodium sulfide, the aminoacrylate intermediate was pre-
formed by treatment of CysM (14 μM) with a solution of O-phospho-L-serine (11 μM) 
under single turnover conditions. This was then mixed with solutions of CysO-COSH 
(25 – 250 μM) or sodium sulfide (100 μM – 15 mM). In the case of CysO-COSH, the 
lowest concentration used (25 μM) was not under pseudo-first order conditions. For 
CysO-COSH, the aminoacrylate and CysO-COSH solutions were mixed rapidly in a 
stopped-flow device and the decay of absorbance at 465 nm due to reaction of the 
aminoacrylate intermediate was observed. In the case of sodium sulfide, the 
aminoacrylate and bisulfide-containing solutions were mixed manually and the decay 
of absorbance was recorded in the presence of the reductant TCEP (2 mM). In both 
cases these decays were fit by non-linear regression to single exponential functions to 
yield the first order rate constants for quenching of the aminoacrylate under the 
varying conditions of nucleophile concentration. These rate constants were then 
plotted as a function of nucleophile concentration. In the case of CysO-COSH the data 
thus obtained were fit to a line, whereas in the case of bisulfide the dependence of the 
first order rate constants on the nucleophile concentration was fit to a hyperbola. 
24 
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CHAPTER 2 
Biochemical characterization of the HpxO enzyme from Klebsiella pneumoniae, a 
novel FAD–dependent urate oxidase.1 
 
2.1. Introduction 
Catabolism of purine nucleobases is an important mechanism for nitrogen assimilation 
by many organisms when their growth is limited by the availability of ammonia or 
alternative nitrogen sources (1, 2). The bases are converted to hypoxanthine 2.1 or 
xanthine 2.2, then oxidized to uric acid 2.3 (Figure 2.1). The steps to this point are 
ubiquitous in Nature but humans, amongst other organisms, lack the ability to 
metabolize urate to allantoin 2.6 (3). In contrast, the pathway from urate, in a variety 
of microbes and plants, has been intensively studied and proceeds under aerobic 
conditions in three steps from urate to allantoin 2.6. The first step is the hydroxylation 
of urate, catalyzed by urate oxidase (1, 4, 5). In all previously-studied cases, the 
catalytic mechanism of urate oxidase is remarkable in that it does not require a 
cofactor (6). Detailed studies have implicated the electron-rich urate dianion as an 
enzyme-bound intermediate which can react spontaneously with molecular oxygen in 
its triplet ground state, forming a peroxide intermediate. Analogy has thus been made 
between urate and the isoalloxazine moiety of flavins which in its reduced form 
undergoes a similar oxidation. 
 
____________________________________ 
1Reproduced with permission from O’Leary, S. E., Hicks, K. A., Ealick, S. E., Begley, 
T. P. (2009) Biochemical characterization of the HpxO enzyme from Klebsiella 
pneumoniae, a novel FAD-dependent urate oxidase, Biochemistry 48, 3033–3035. 
Copyright 2009, American Chemical Society. 
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In extension of the analogy, EPR spin trapping experiments have suggested the 
presence of transient radical intermediates in the steps leading to the urate 
hydroperoxide intermediate (7). 
The urate oxidase product, 5-HIU 2.4, is unstable in aqueous buffer, hydrolyzing 
spontaneously to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) 2.5 (8). 
Notwithstanding the operation of this spontaneous reaction under physiological 
conditions, all known organisms which express the cofactorless urate oxidase also 
Figure 2.1. Purine catabolic pathway from hypxanthine to allantoin. 
 
possess a hydrolase enzyme which accelerates the conversion of 2.4 to 2.5. The 
decarboxylation of OHCU 2.5 to allantoin 2.6 is also spontaneous under physiological 
conditions, but nonenzymatically produces racemic allantoin (3). A stereospecific 
decarboxylating enzyme, which produces only (S)-allantoin, is found in organisms 
with urate oxidase and 5-HIU hydrolase (9, 10); some organisms also possess a 
racemase enzyme (1, 11). Allantoin can be futher catabolized to ammonia and carbon 
dioxide, thus utilizing the remaining nitrogen atoms in the imidazoline ring (1,12). 
While the enzymology of the pathway outlined above has been thoroughly 
investigated, two very recent reports (13, 14) have suggested that the pathway from 
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hypoxanthine to allantoin, involving the same intermediates but different catalytic 
strategies for their interconversion, exists in the facultative anaerobe Klebsiella 
pneumoniae, a ubiquitous human pathogen (15, 16). In particular, the enzyme 
proposed to catalyze the conversion of urate to 5-hydroxyisourate 2.4 shows sequence 
similarity to FAD-dependent monooxygenases catalyzing the hydroxylation of 
aromatic compounds. It was noted that the enzyme sequence includes residues which 
are conserved across this group of enzymes that contain an FAD-binding domain and a 
small NADH-binding domain (Figure 2.2) (17). Both groups proposed that HpxO 
catalyzes the hydroxylation of urate by a mechanism similar to the well-studied p-
hydroxybenzoate hydroxylase (18, 19), and that HpxO is the first example of an FAD-
dependent urate oxidase. However, de la Riva et al. also reported that in their study, 
cells with hpxO, expressed from a high-copy plasmid, lacked discernible urate oxidase 
activity (14). 
 
2.2. Results and discussion. 
2.2.1. HpxO is a flavoprotein. 
To test the prediction that HpxO is an FAD-dependent urate oxidase, we cloned, 
heterologously overexpressed and purified the recombinant, N-terminally His6-tagged 
protein, and then reconstituted its activity in vitro. The isolated protein was more than 
95% pure, as determined by SDS-PAGE analysis (Figure 2.2A), with a molecular 
weight (including the N-terminal tag) of ~45 kDa. The HpxO protein solution, after 
gel filtration, was yellow, suggesting the presence of a tightly-bound cofactor. The 
UV-visible spectrum of the protein solution (Figure 2.2B) had maxima at 454, 381, 
273 and <220 nm. Reverse-phase HPLC analysis of the small molecule released from 
the protein upon heat denaturation confirmed that the cofactor was FAD (Figure 2.2C, 
2.2D). We determined the HpxO:FAD stoichiometry by measurement of the FAD-
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derived absorbance in a solution of HpxO denatured by the addition of urea to a 
concentration of 6 M. The 450 nm absorbance (ε450 = 9.7 mM−1 cm−1, Figure 2.3) was 
used to compute the FAD- derived 280 nm absorbance (A280/A450 = 1.84), which in 
turn was subtracted from the total absorbance at 280 nm to give the protein absorbance 
at that wavelength. The protein absorbance was then used to determine its 
concentration based on the theoretical HpxO molar extinction coefficient (57.4 mM−1 
cm−1) at 280 nm (20). The FAD concentration and the protein concentration agreed to 
within 10%, and also agreed with the protein concentration determined by the 
Bradford method (21). Taken together, these results suggest that the FAD:HpxO 
stoichiometry is 1:1.  
Figure 2.2. Isolation and cofactor content of recombinant K. pneumoniae HpxO. 
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2.2.2. Urate oxidase activity of HpxO. 
Having demonstrated that HpxO is a flavoprotein, we investigated its catalytic activity 
towards uric acid. Treatment of uric acid with HpxO in the presence of NAD(P)H 
resulted in a decrease in the  340 nm absorbance, consistent with the oxidation of the 
NAD(P)H to NAD(P)+. The rate of this decrease in A340 depended linearly on the 
enzyme concentration and could be saturated at high concentrations of urate or 
NADH. At saturating concentrations of NADH (1.5 mM, see below) the 385 nm  
Figure 2.3. Determination of absorption characteristics of flavin adenine dinucleotide 
(FAD) under conditions used to produce denatured HpxO. A: UV-visbile spectra of 
standard solutions of FAD (1 − 40 μM) in 6 M urea buffered with 0.1 M potassium 
phosphate, pH 8.0; B: Beer-Lambert plot for the FAD absorbance at 450 nm. The blue 
circles indicate samples where BSA was added to a final concentration of 50 μg/mL to 
ensure that the presence of protein did not alter the observed absorbance. The linear fit 
gives ε450 = 9.7 mM−1 cm−1. Additionally, the A280/A450 ratio was 1.84. 
 
absorbance was monitored (ε385 = 0.745 mM−1 cm−1). When urate was omitted there 
was a detectable, enzyme-dependent rate of NAD(P)H oxidation, but this was not 
significant relative to the rates observed in the presence of urate. A fit of the kinetic 
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data when NADH was used as the nucleotide cosubstrate to the Michaelis–Menten 
equation gave values for Km and kcat of 42 ± 8 μM and 42 ± 2 s−1 (kcat/Km = 1.0 ± 0.2 
μM−1 s−1) for urate (Figure 2.4). Previous studies on the stability of the proposed 
HpxO product, 5-HIU 2.4, have shown that it should react spontaneously under our 
assay conditions to form allantoin; full conversion should occur in ~1 h. HPLC 
analysis of samples of urate, incubated with HpxO for 1 h in the presence of NADPH 
followed by removal of the enzyme, confirmed the presence of allantoin and NADP+ 
(Figure 2.5E). Assignment of the product as allantoin was confirmed by comparison 
with an authentic standard and also with the reaction products from a commercially 
available, FAD-independent urate oxidase (Figure 2.5D). Control experiments where 
urate was omitted confirmed that HpxO can catalyze the slow conversion of NADPH 
to NADP+ in the absence of urate (Figure 2.5A-2.5C). These results suggest 5-HIU 2.4 
to be the immediate product of the HpxO-catalyzed reaction. This proposal is further 
supported by the presence of genes in the hpx cluster which are proposed to encode 5-
HIU hydrolase and OHCU decarboxylase. 
Analysis of the time course of the HpxO catalyzed reaction from uric acid to allantoin 
by UV–visible spectrophotometry also indicated that 5-HIU and OHCU accumulated 
and decayed on the expected time scales (Figure 2.6). 
 
2.2.3. Selectivity for NADH as the reduced nicotinamide substrate. 
HpxO shows selectivity (V/K ratio of ~10) for NADH over NADPH. The HpxO 
steady-state rate showed no saturation at concentrations of NADPH up to 1 mM, 
suggesting this value as a lower limit for Km,NADPH. A linear fit to the rate-
concentration data gave an estimate of 9.7 ± 0.3 mM−1 s−1 for the kcat/Km value (Figure 
2.7A). In contrast the steady-state rate showed saturation at NADH concentrations 
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above 0.5 mM, and a hyperbolic fit to this data gave 125 ± 30 mM−1 s−1 as an estimate 
of kcat,NADH/Km,NADH, (Figure 2.7B). 
 
 
 
  
Figure 2.4. Steady-state kinetics of urate (UA) hydroxylation catalyzed by HpxO. All 
stocks were prepared in 0.1 M potassium phosphate, pH 8.0. Concentrations are final 
in a volume of 0.4 mL. Enzyme (40 μL, 40 nM) was pre-mixed with uric acid (0 – 50 
μL, 0 – 250 μM) and buffer was added to a total volume of 340 μL. The reaction was 
initiated by addition of NADH (60μL, 1.5 mM), then the sample was manually mixed 
and the 385 nm absorbance was monitored as a function of time. The rates of NADH 
oxidation at the various concentrations of UA were determined by linear fits to the 
absorbance-time data, and these rates were fit to the Michaelis-Menten equation. The 
hyperbolic fit gives kcat = 42 ± 2 s−1 and Km = 42 ± 8 μM. 
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Figure 2.5. HPLC analysis of HpxO-catalyzed oxidation of uric acid in the presence 
of NADPH. 
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Figure 2.6. Time course of HpxO-catalyzed reaction of urate monitored by UV-visible 
spectrophotometry. Both the sample and reference cell contained NADH (0.2 mM) 
and HpxO (0.5 μM). The reaction mixture additionally contained 0.2 mM uric acid 
(λmax = 290 nm, 230 nm). The traces shown were recorded before the addition of 
HpxO (uppermost trace) and then at 15 s, 100 s and (100 + 170n) s after addition of 
enzyme, where 1 ≤ n ≤ 29. The spectra show initial rapid conversion of uric acid to a 
species with an absorbance maximum around 300 nm (reported for HIU, 302 nm, ref. 
5), followed by the conversion of this species (τ½ ~ 500 s) to an intermediate with 
maximal absorbance at ~230 nm (reported for OHCU, < 240 nm). This intermediate 
then reacts further (τ½ ~ 500 s) with an associated decrease in the 230 nm absorbance. 
The absorption characteristics of the intermediates and the rates of their 
interconversion are consistent, based on previous studies, with the 5-HIU → OHCU 
→ allantoin model proposed for decomposition of the 5-HIU HpxO reaction product. 
Inset: Single-wavelength time courses at 294 nm (with absorbance contributed by uric 
acid, 5-HIU and NADH) and 230 nm (uric acid, 5-HIU and OHCU). The small band 
centered around 276 nm is due to HpxO. 
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2.2.4. Formation of the HpxO dihydroflavin intermediate under anoxic conditions. 
We also sought to demonstrate the formation of the dihydroflavin intermediate 2.8 by 
the reaction of NADPH with HpxO under anaerobic conditions. HpxO was incubated 
in the presence of glucose, glucose oxidase and catalase for 15 minutes in a sealed 
spectrophotometer cuvette prior to the introduction of an excess of NADPH. The 
absorbance spectrum in the 400-550 nm region was recorded after a further incubation 
of 10 minutes to allow for consumption of residual oxygen. The spectrum (Figure 2.8) 
showed complete removal of the 454 nm-centered absorbance, consistent with the 
formation of dihydro-FAD 2.8. Considered along with the evidence that molecular 
oxygen is a substrate and the precedent available from previously well-studied 
systems, this result suggests that the mechanism presented in Figure 2.9 is in operation 
during the HpxO catalytic cycle. 
 
2.2.5. Estimation of kcat/Km for molecular oxygen. We estimated the Km for 
molecular oxygen for the HpxO reaction to be no more than 0.05 mM, yielding a value 
of kcat/Km of at least ~0.7 μM−1 s−1 (Figure 2.10). This value is at least one order of 
magnitude greater than the equivalent value for the cofactor-independent urate oxidase 
(0.034 μM−1 s−1). This suggests that the enzyme activity may have evolved to allow 
efficient flux through the purine catabolic pathway when the organisms are living in 
conditions where oxygen is not abundant.  
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Figure 2.7. Dependence of HpxO steady-state rate on concentrations of NADPH and 
NADH. (A) Dependence on NADPH concentration. Enzyme (0.25 μM) was pre-
mixed with urate (0.5 mM). The appropriate volume of NADPH solution was then 
added from a 10 mM stock to initiate the reaction after addition of buffer (0.1 M 
potassium phosphate, pH 8.0) to produce a total volume of 0.5 mL The rates of 
NADPH oxidation were measured by monitoring the absorbance at 340 nm (0 – 0.2 
mM NADPH) or at 385 nm (>0.2 mM NADPH), using ε340 = 6.22 mM−1 cm−1 and ε385 
= 0.745 mM−1 cm−1. A linear fit to the low-concentration data (≤ 200 μM) gives 9.7 ± 
0.3 mM−1 s−1; (B) Dependence on NADH concentration. Conditions were as for 
NADPH, with the exception that the enzyme concentration was 25 nM. The 
hyperbolic fit estimates kcat/Km = 125 ± 30 mM−1 s−1. 
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Figure 2.8. Reaction of HpxO-bound FAD with NADPH under anaerobic conditions. 
NADPH (final concentration 0.50 mM) was added to a solution, in a sealed quartz 
spectrophotometer cuvette, containing HpxO (6 μM), glucose (initial concentration 10 
mM), glucose oxidase (10 units) and catalase (12.5 units), in 0.1 M potassium 
phosphate, pH 8.0. The red trace shows the 400 – 550 nm spectrum recorded 
immediately after the addition of the NADPH. The blue trace shows the spectrum of 
the same sample recorded after incubation for ~10 minutes. 
 
Figure 2.9. Proposed reaction mechanism for HpxO.  
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 Figure 2.10. Estimation of Km for molecular oxygen for the HpxO-catalyzed reaction 
of urate. HpxO (0.012 – 0.06 mM) was added to solutions of uric acid (0.5 mM) and 
NADH (1 mM) in 0.1 M potassium phosphate buffer, pH 8.0. (A) The absorbance at 
385 nm was monitored until it had reached equilibrium on the time scale of the 
experiment (<600 s), corresponding to almost complete deoxygenation of the buffer 
by the urate oxidase reaction. Inset: Full time course (58 nM HpxO) showing 
saturation of the steady-state rate at [O2] ≥ 0.05 mM. A slow depletion of NADH on 
longer time scales reported on the rate of diffusion of oxygen into the buffer and 
spontaneous oxidation of the NADH. Interpolation of the linear time course data to the 
point of addition of the enzyme (t = 0 s) yielded the initial oxygen concentration from 
the difference in NADH concentrations (240 ± 6 μM, averaged over four enzyme 
concentrations) between the t = 0 and equilibrium concentrations. (B) A plot of the 
observed initial rate (from a linear fit to the A385 data at short times) as a function of 
kcat[E]o has slope [S]o/(Km + [S]o), where [E]o is the HpxO concentration, kcat is the 
turnover number (42 ± 2 s−1), [S]o is the initial substrate concentration and Km is the 
Michaelis constant. The slope q of the resulting linear plot allows estimation of Km = 
([S]o – q[S]o)/q. 
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2.3. Experimental. 
2.3.1. Protein overexpression and purification 
The plasmid coding the His6-TEV-HpxO polypeptide was transformed into competent 
Escherichia coli BL21(DE3) using the heat-shock method. Briefly, 100 μL of 
competent cells were added to 2 μL of DNA in a sterile microcentrifuge tube. The 
mixture was incubated on ice for 30 minutes, then heat-shocked at 37 °C for two 
minutes. After incubation at room temperature for 10 minutes, 1 mL of sterile Luria-
Bertani (LB) broth was added and the mixture was incubated at 37 °C for 75 minutes. 
After this incubation, the culture was centrifuged for five minutes at 8,000 × g and 1 
mL of the supernatant was removed. The pellet was resuspended in the remaining 0.1 
mL and this was plated out onto LB agar containing 40 mg/L kanamycin sulfate. The 
plate was incubated at 37 °C overnight. For overexpression of the protein, an 
overnight 37 °C starter culture in 10 mL LB broth (from a single colony of the 
transformants) was inoculated into 1 L of LB and grown at 37 °C until the optical 
density at 600 nm was 0.6. Protein overexpression was then induced by addition of 
isopropyl β-thiogalactopyranoside (1 mM). Induction was allowed to proceed at 37 °C 
for 6 h. The cells were then harvested by centrifugation and stored at −80 °C. 
Purification was effected by Ni2+-nitrilotriacetic acid (Ni-NTA) chromatography. The 
cell pellet from overexpression was resuspended in approximately 30 mL of lysis 
buffer (0.05 M NaH2PO4, 0.3 M NaCl and 10 mM imidazole, pH 8.0). Approximately 
5 mg of FAD were added to the suspension at this time, along with approximately 10 
mg of lysozyme. The cells were lysed by sonication (five cycles of 30 s duration 
during which 1.5 s sonicator pulses at medium power were followed by 1.5 s pauses) 
whilst the temperature was maintained at <10 °C. The resulting suspension was 
centrifuged (17,000 rpm, 25 minutes) and the supernatant was filtered through a sterile 
syringe filter (pore size 0.22 μm). The filtrate was then loaded onto the pre-charged 
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Ni-NTA resin (His•Bind, Novagen; bed volume 4.0 mL). The chromatography was 
carried out at room temperature but all buffers were kept at 4 °C on ice. The loaded 
resin was washed with 10 column volumes of lysis buffer and then with 15 column 
volumes of a buffer composed of 0.05 M NaH2PO4, 0.3 M NaCl and 20 mM 
imidazole, pH 8.0. The yellow protein was then eluted using a buffer composed of 
0.05 M NaH2PO4, 0.3 M NaCl and 250 mM imidazole, pH 8.0. Yellow fractions were 
pooled (total volume ~6 mL) and buffer exchanged into 0.1 M potassium phosphate, 
pH 8.0 (10-DG desalting column, BioRad, Hercules, CA). 
For long term storage (more than 3 days), 0.1 mL aliquots composed of 0.05 mL 
protein solution and 0.05 mL 80% glycerol were frozen in dry ice and stored at −80 
°C. 
 
2.3.2. Determination of ε450 for FAD in 6 M urea buffered with 0.1 M potassium 
phosphate, pH 8.0. 
All buffered urea solutions were freshly prepared. Solid urea was dissolved to a final 
concentration of 6 M in 0.1 M potassium phosphate, pH 8.0. Serial dilutions from a 
0.1 M FAD stock in the buffered urea solution were used for determination of the 
FAD absorbance spectra. Under these conditions the long-wavelength absorbance 
maximum was found at 450 nm. A Beer-Lambert plot of the absorbance-concentration 
data gave a value for ε450 of 9.7 mM−1 cm−1. As a control for the effects of protein on 
the absorbance, BSA was added in a separate experiment to some of the samples, to a 
final concentration of 50 μg/mL. The presence of the BSA did not affect the 
absorbance at 450 nm. At all concentrations of FAD the A280/A450 ratio was 1.84. 
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2.3.3. Computation of recombinant HpxO ε280 from the His6-TEV-HpxO primary 
sequence. 
The amino acid sequence of the recombinant, N-terminally tagged HpxO is given 
below: 
 
MGSDKIHHHHHHSSGENLYFQGHMKAIVIGAGIGGLSAAVALKQSGIDCDVYEAVKEIKPVGA
AISVWPNGVKCMAHLGMGDIMETFGGPLRRMAYRDFRSGENMTQFSLAPLIERTGSRPCPVSR
AELQREMLDYWGRDSVQFGKRVTRCEEDADGVTVWFTDGSSASGDLLIAADGSHSALRPWV
LGFTPQRRYAGYVNWNGLVEIDEALAPGDQWTTFVGEGKRVSLMPVSAGRFYFFFDVPLPAG
LAEDRDTLRADLSRYFAGWAPPVQKLIAALDPQTTNRIEIHDIEPFSRLVRGRVALLGDAGHST
TPDIGQGGCAAMEDAVVLGAVFRQTRDIAAALREYEAQRCDRVRDLVLKARKRCDITHGKD
MQLTEAWYQELREETGERIINGMCDTILSGPLG 
 
Analysis of this sequence by the method of Pace et al. (20) gives an estimate of ε280 = 
57.4 mM−1 cm−1 for the HpxO polypeptide. This was computed using the formula 
 
ε280 (M−1 cm−1) = 5500nTrp + 1490nTyr + 125nCystine 
 
where ni is the total number of the ith residue in the protein sequence. The potential 
contribution from cystine residues was omitted in the analysis. 
 
2.3.4. Steady-state kinetics with urate. 
All stock solutions were prepared in 0.1 M potassium phosphate, pH 8.0 (“buffer”). 
Concentrations are final after mixing of all sample components. The concentration of 
NAD(P)H stocks was standardized using a molar extinction coefficient at 340 nm of 
6.22 mM−1 cm−1. For measurement of the steady-state rate, HpxO (40 nM, 0.04 mL of 
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a 400 nM stock) was pre-incubated with uric acid (0 – 70 μL of a 2 mM stock) and 
buffer was added to a final volume of 0.34 mL. The reaction was then initiated by 
addition of NADH (1.5 mM, 0.06 mL of a 10 mM stock), followed by rapid manual 
mixing. The absorbance was then measured at 285 nm as a function of time after 
mixing. The rates of the linear decreases in NADH concentration (ε385 = 0.745 mM−1 
cm−1) at each of the urate concentrations were obtained by linear regression. These 
were then plotted as a function of the urate concentration and the resulting rate-
concentration dependence was fit to the Michaelis-Menten equation in order to 
determine the kcat (42 ± 2 s−1) and Km (42 ± 8 μM) values. The errors are errors to the 
hyperbolic fit. 
 
2.3.5. Steady-state kinetics with NAD(P)H. 
All stock solutions were prepared in 0.1 M potassium phosphate, pH 8.0 (“buffer”). 
Concentrations are final after mixing of all sample components. In the case of 
NADPH, enzyme (0.25 μM, 0.01 mL of a 0.0126 mM stock) was pre-mixed with 
urate (0.5 mM, 0.125 mL of a 2 mM stock). The appropriate volume of NADPH 
solution (0.02 – 1 mM, 0 –50 μL of a 10 mM stock) was added to initiate the reaction 
after addition of buffer to produce a final volume of 0.5 mL. The rates of NADPH 
oxidation were measured by monitoring the absorbance at 340 nm (0 – 0.2 mM 
NAD(P)H) or at 385 nm (>0.2 mM NAD(P)H), using ε340 = 6.22 mM−1 cm−1 and ε385 
= 0.745 mM−1 cm−1. The measured rate at 0.2 mM substrate did not change when 
monitored at these two different wavelengths. A linear fit to the low-concentration 
NADPH data (≤ 200 μM) gives an estimate of kcat/Km of 9.7 ± 0.3 mM−1 s−1. Reaction 
conditions in the case of NADH were as described above for NADPH, with the 
exception that the enzyme concentration was 25 nM. The hyperbolic fit estimates 
kcat/Km = 125 ± 30 mM−1 s−1. 
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2.3.6. Anaerobic reduction of HpxO with NADPH. 
A solution was prepared in 0.1 M potassium phosphate buffer, pH 8.0, which 
contained HpxO (6 μM), glucose (initial concentration 10 mM), glucose oxidase (10 
units) and catalase (12.5 units). This solution was placed in a quartz 
spectrophotometer cuvette which was sealed with parafilm. The solution was allowed 
to equilibrate for 15 minutes, in order to remove the majority of dissolved oxygen. 
After this period the 400 – 550 nm spectrum of the solution was recorded. Next, a 
syringe was used to introduce a solution of NADPH (final concentration 0.50 mM) 
through the parafilm layer into the sealed cuvette. The resulting mixture was allowed 
to equilibrate for 10 minutes, in order to allow consumption of the small amounts of 
oxygen introduced by addition of the NADPH and by the mixing of the sample after 
NADPH addition. During this equilibration period, the absorbance peak centered at 
450 nm decreased steadily in intensity, and this decrease was accompanied by a 
decrease in the absorbance at 340 nm derived from the NADPH (data not shown). 
These decreases were interpreted as reporting on the consumption of NADPH and the 
residual oxygen in the sample by completion of one or more rounds of catalysis. Once 
the absorbance had equilibrated, the 400 – 550 nm spectrum was re-recorded. 
 
2.3.7. HPLC analysis of HpxO reaction products. 
All reactions were assayed by reverse-phase HPLC on an Agilent 1100 HPLC system 
equipped with a quaternary pump and a 1.0 mL sample loop. The system also had a 
diode array UV-Vis detector (190 – 640 nm) and a fluorescence detector. The 
stationary phase was a Supelcosil LC-18-T column (15 cm × 4.6 mm, 3 μm particles), 
maintained at room temperature (21 ± 1 °C). The LC eluent consisted of a gradient of 
methanol in 10 mM potassium phosphate buffer, pH 6.6. In the analytical method the 
percentages P and M of phosphate buffer and methanol (balance water) at time t 
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varied according to the following scheme: {t,P,M}: {0,100,0}, {4,90,0}, {9,60,15}, 
{14,10,65}, {16,100,0}, {21,100,0}. 
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 CHAPTER 3 
Insights into the catalytic mechanism of HpxO from X-ray crystallographic 
studies and steady-state kinetic analysis of active site mutants. 
 
3.1. Introduction 
Our initial studies (1) on HpxO confirmed its assignment as a flavin adenine 
dinucleotide (FAD)-dependent urate oxidase (Figure 3.1). The primary sequence of 
HpxO, even in the absence of the biochemical data, allowed the reasonable proposal of 
its cofactor requirement. This was due to sequence similarity between HpxO and a 
variety of enzymes which catalyze similar oxygenation reactions, the prototype of 
which is 4-hydroxybenzoate hydroxylase (PHBH) (2). Such enzymes are known to 
possess conserved domains (and corresponding amino acid sequences) for binding of 
FAD and the nicotinamide co-substrate. 
However, this homology information and the initial biochemical characterization did 
not provide detailed information on the chemical and kinetic mechanisms of formation 
of 5-hydroxyisourate 3.2 at the HpxO active site, nor did they identify the residues 
important for catalysis of oxygen transfer to the HpxO-bound uric acid 3.1. These 
residues vary between members of the FAD-dependent monooxygenase family, owing 
to the chemical diversity of the enzymes’ substrates, which necessitates differing 
arrangement of amino acid side chains at the active site to facilitate binding, substrate 
activation, and oxygenation (3,4). 
Figure 3.1. HpxO-catalyzed reaction of urate 3.1 and subsequent decomposition of 
HpxO-produced 5-hydroxyisourate 3.2 to allantoin 3.3. 
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A further feature of members of this enzyme family is their ordered kinetic pathway, 
wherein binding of the substrate to be oxygenated triggers a conformational change in 
the protein that results in the movement of the FAD isoalloxazine ring to an “out” 
position where it is accessible for reduction by NAD(P)H (5). This “coupling” 
between substrate binding and flavin reduction has presumably evolved to prevent 
uncontrolled depletion of cellular NAD(P)H and the concomitant formation of 
hydrogen peroxide resulting from its abortive elimination from the flavin 
hydroperoxide intermediate in the absence of a bound oxygenation substrate. The 
coupling has been shown to be mediated through a complex network of amino acid 
residues and water molecules extending from the active site which is sensitive to the 
presence of substrate and can trigger the requisite conformational changes (6). 
Catalytically-relevant active site residues can thus be notionally grouped into two sets, 
consisting of amino acids important for the specificity and catalysis of the oxygen 
transfer reaction, and those important for maintaining the fidelity of the coupling 
between substrate binding and flavin reduction. Analysis of the structures of the HpxO 
protein in the absence and presence of uric acid could thus facilitate assignment of 
active site residues as members of one (or potentially both) of these sets. Kinetic 
studies on appropriately-chosen mutants of such residues can then confirm the 
assignment based on the structural data, providing an integrated picture on the HpxO 
catalytic mechanism. Here we report the results of these studies. 
 
3.2. X-ray crystal structure of wild-type HpxO. 
The X-ray crystal structure of the wild-type HpxO protein was solved by Katherine 
Hicks, Cornell University. This structure confirmed that HpxO co-purifies with FAD, 
and also that the FAD:HpxO stoichiometry is 1:1, as determined from the biochemical 
studies. The FAD was bound by the enzyme in a manner similar to related proteins 
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such as 4-hydroxybenzoate hydroxylase. The overall structural features of the protein 
are consistent with other members of the FAD-dependent monooxygenase family, 
which possess an N-terminal domain important for FAD and NAD(P)H binding, a 
central domain composed of a series of antiparallel β-sheets involved in substrate 
binding, often referred to as the “monooxygenase domain”, and a C-terminal domain 
thought to be involved in dimerization of the protein in solution. The C-terminal 
domain exhibits variability in length and amino acid composition between members of 
the FAD-dependent monooxygenases. 
Figure 3.2. X-ray crystal structure of the HpxO-FAD-urate ternary complex. 
 
3.3. X-ray crystal structure of the HpxO-FAD-urate ternary complex. 
The X-ray crystal structure of the HpxO-FAD-urate ternary complex was also solved 
(Figure 3.2). This structure revealed uric acid bound at the HpxO active site (Figure 
3.3) in close proximity to the isoalloxazine portion of the FAD. The urate interacts 
with a number of active site residues, principally involving hydrogen bonding 
interactions with the purine endocyclic nitrogen atoms and the exocyclic oxygen 
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atoms. A number of ordered water molecules were also observed in the active site. 
Several of these participate in a H-bond network which involves the urate molecule 
and the side chains of a number of polar active site residues. Individual interactions in 
this network are discussed in the context of the relevant active site residues, below. In 
4-hydroxybenzoate hydroxylase, a hydrogen bond network extending from the active 
site to the protein surface has been shown to play a role in the conformational changes 
produced by substrate binding which allow movement of the FAD to its “out” position 
and its subsequent reduction by NAD(P)H. 
 
 
Figure 3.3. HpxO active site indicating positions of the FAD isoalloxazine ring, urate, 
and the residues mutated in the present study. 
 
55 
3.4. Choice of active site mutants for kinetic characterization. 
Based on our inspection of the enzyme active site in the HpxO-FAD-urate complex, 
we selected seven residues which were likely to be important for catalysis, owing to 
either their direct interaction with, or proximity to, the uric acid molecule or the 
isoalloxazine portion of the FAD. The rationale for the choice of individual residues is 
discussed with the results, below. The kinetic data are summarized in Table 3.1. 
 
3.5. HpxO R204K/Q mutants: activity and uncoupling. 
The R204 residue is within hydrogen bonding distance (2.67 Å) of the uric acid N1 
atom (Figure 3.4). It can thus serve as a general base to facilitate proton transfer from 
N1 of the urate molecule, which is likely to occur in concert with oxygenation of the 
urate C5 atom. Its positively charged side chain is also well-positioned to stabilize the 
negative charge which formally accumulates on the N1-C2-O2′ region of the urate 
during the oxygen transfer step. The residue may thus play a role in stabilization of the 
urate N1-C2-O2′ enol(ate) tautomer, both by hydrogen bonding and electrostatic 
interactions. We prepared the R204K and R204Q mutants of HpxO to investigate 
whether these interactions are important for catalysis. 
Figure 3.4. Location of HpxO R204 and D293 residues in the enzyme active site. 
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Both the R204K and R204Q mutants co-purified with sub-stoichiometric occupancy 
of FAD, The R204Q mutant could be reconstituted with the cofactor by a short 
incubation. The excess cofactor could then be removed by gel filtration. When the 
FAD-reconstituted proteins were treated with uric acid and NADH, the order of 
activity with respect to formation of allantoin 3.3 (Figure 3.5) was wt > R204K > 
R204Q (Table 3.1). This was consistent with the proposal that a cationic group in this 
region of the active site is important for catalysis. 
However, these mutants showed a reversed trend with respect to their rates of NADH 
consumption. While wild-type HpxO tightly couples NADH and substrate oxidation, 
the R204K, and especially the R204Q mutants, showed elevated levels of uncoupling 
in this regard. Steady-state kinetic studies on HpxO R204Q indicated that the presence 
of uric acid in fact had little or no effect on the kinetics of oxidation of NADH (Figure 
3.6). The KM value for NADH was 0.64 ± 0.04 mM, close to the value for the wild-
type enzyme in the presence of saturating concentrations of urate. The kcat value was 
0.26 s−1, two orders of magnitude slower than the kcat for urate consumption with 
wtHpxO. If the “uncoupling ratio” is defined as the ratio of the quantity of NADH 
oxidized to the quantity of allantoin formed in the enzymes’ steady-state turnover, 
then this ratio is approximately one order of magnitude greater for HpxO R204K than 
for wild-type HpxO, and a further order of magnitude greater in the case of HpxO 
R204Q. This suggests that the R204 residue plays an important role in both the 
oxygen transfer step of the HpxO catalytic cycle and also in mediating the 
conformational change which translates substrate binding to flavin motion and 
reduction.  
The R204 side chain potentially interacts with D293, in a salt bridge-type interaction. 
However, the electron density for these residues in the HpxO-FAD-urate ternary 
complex shows that the residues are not properly aligned to form the salt bridge. One 
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of the carboxyl oxygen atoms of D293 is located 3.51 Å away from the guanidinium 
group of R204, suggesting that these two residues could also be involved in a 
hydrogen bonding interaction. 
Figure 3.5. Reverse-phase HPLC analysis of HpxO R204Q/K conversion of urate to 
allantoin compared with wild-type enzyme. The enzymes (~1 μM) were incubated 
with urate (1 mM), NADH (5 mM) and FAD (0.1 mM) for 3 h at 25 °C. The protein 
was then removed by centrifugal ultrafiltration before analysis. Chromatograms were 
detected using the UV absorbance at 210 nm. 
 
Thus the R204 residue may be notionally “bifunctional” in the case of the HpxO 
catalytic cycle, i.e., involved in gating the FAD “in” to “out” transition, and in a 
kinetic deprotonation of the urate required for oxygenation. An equivalent, charged 
residue is not observed in the structure of the 4-hydroxybenzoate hydroxylase active 
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site, where a complementary charged group with which it would interact is not present 
in the 4-hydroxybenzoate substrate. 
 
 
 
Figure 3.6. Steady-state oxidation of NADH catalyzed by HpxO R204Q. The enzyme 
(1.5 μM) was treated with NADH (0 – 1.5 mM) in 0.1 M potassium phosphate buffer, 
pH 8.0 at 25 ± 1 °C. The change in absorbance at 385 nm was recorded as a function 
of time after mixing. a) Time course data for the NADH oxidation. The linear phase 
was fit by linear regression to give the steady-state rate of NADH consumption at the 
varying concentrations of NADH. The presence of urate did not significantly affect the 
steady-state rate of urate consumption (top trace). b) Michaelis-Menten plot. The KM 
for NADH was 0.64 ± 0.04 mM, kcat was 0.26 ± 0.006 s−1, with kcat/KM ~ 10−5 μM−1 
s−1, 
 
Crystallographic studies are underway to determine the position of the FAD 
isoalloxazine ring in the HpxO R204Q-FAD-urate ternary complex, which the kinetic 
studies suggest may be largely in the “out” position. 
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3.6. HpxO D293N. 
D293 potentially interacts with the R204 residue as discussed above (Figure 3.4), 
along with the side chain of Y176 (see section 3.9).  
In the context of the results for the R204K/Q mutants, it could be proposed that D293 
may be involved in modulation of the pKa of the side chain of R204, in an interaction 
which would optimize proton transfer from the urate N1 atom accompanying 
oxygenation at C5. Additionally, D293 could be involved, along with R204, in the 
network of residues responsible for global conformational changes resulting in FAD 
reduction triggered by substrate binding. 
Figure 3.7. Michaelis-Menten steady-state kinetics of urate oxidation catalyzed by 
HpxO D293N. a) Dependence of steady-state rate on NADH concentration in the 
presence of 1 mM urate. The enzyme (0.6 μM) was treated with NADH (0 – 1.5 mM) 
in 0.1 M potassium phosphate buffer, pH 8.0 at 25 ± 1 °C. The change in absorbance 
at 385 nm was recorded as a function of time after mixing. The KM for NADH was 
293 ± 62 μM. b) Dependence of steady-state rate on urate concentration in the 
presence of 1.5 mM NADH under conditions otherwise identical to (a). The KM for 
urate was 103 ± 19 μM. The kcat value was 0.46 ± 0.02 s−1 
 
The D293N mutant showed impaired catalytic activity (Figure 3.7). The KM for 
NADH was 293 ± 62 μM, approximately a two-fold decrease compared with the wild-
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type enzyme. The KM for urate was 103 ± 19 μM, an approximately two-fold increase 
over wtHpxO. The kcat/KM value for urate was ~0.007 μM−1 s−1, ~103-fold less than for 
wtHpxO. Additionally, the FAD occupancy in the “as-isolated” protein was low, and 
this mutant could not be stably reconstituted with FAD as in the case of HpxO R204Q. 
However, the steady-state rate was insensitive to the presence of exogenous FAD in 
the 0 – 0.03 mM range (Figure 3.8). 
 
Figure 3.8. Changes in 385 nm absorbance due to oxidation of NADH by HpxO 
D293N in the presence of varying concentrations of FAD. 
 
3.7. HpxO Y216F 
The Y216 residue is appropriately positioned to hydrogen bond to the O8′ of the urate 
anion at the HpxO active site (2.76 Å), and also to an ordered water molecule which is 
the first in a chain of such molecules that extends outward from the active site to the 
protein surface (Figure 3.9).  
The residue is located on one of the antiparallel β-sheets which form the 
“monooxygenase domain” of the protein. The amino acid residues in this domain are 
thought to be somewhat variable, in response to the necessity to bind different 
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substrates for oxygenation at the active site. The Y216 interaction with urate replaces 
the interaction of an arginine residue with the carboxylate group of 4-hydroxybenzoate 
in the PHBH structure. 
Figure 3.9. Position of Y216 residue at the HpxO active site. 
Figure 3.10. Steady-state kinetics of urate oxidation catalyzed by HpxO Y216F. 
Assays were carried out in 0.1 M potassium phosphate buffer, pH 8.0, in the presence 
of 0.01 mM FAD. The enzyme concentration was 140 nM. a) Dependence of steady-
state rate on NADH concentration in the presence of 0.5 mM urate. The KM for NADH 
was 0.100 ± 0.035 mM; b) Dependence of the steady-state rate on urate concentration 
in the presence of 0.5 mM NADH. The kcat value for urate was 8.4 ± 0.5 s−1. The KM 
for urate was 90 ± 20 μM. These values give an estimate of kcat/KM of 0.093 μM−1 s−1. 
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The HpxO Y216F mutant catalyzed the oxidation of urate and exhibited Michaelis-
Menten kinetics (Figure 3.10). The kcat was reduced by ~5-fold compared with the 
wild type enzyme. Interestingly, the KM for NADH was 0.1 mM, about five times 
tighter than for wtHpxO. This suggests that this residue may be important for 
mediating the conformational changes involved in the flavin “in” to “out” transition 
during catalysis. The KM value for urate was 0.09 mM, about two-fold higher than for 
wtHpxO. This is consistent with the prediction from the crystallographic study that 
Y216 is important for urate binding. The value of kcat/KM for urate was thus reduced 
by a factor of ~10 relative to wtHpxO, whereas that for NADH was essentially 
unchanged. The turnover rate for the Y216 mutant was enhanced by the addition of 
exogenous FAD (0.01 mM, Figure 3.11). 
Figure 3.11. Time course of urate oxidation reactions catalyzed by HpxO Y216F. In 
the full reaction (green trace), the enzyme (250 nM) was incubated with urate (0.5 
mM), NADH (0.1 mM) and FAD (0.01 mM) in 0.1 M potassium phosphate buffer, pH 
8.0. The change in absorbance at 340 nm (decrease, plotted as −ΔA340) was plotted as 
a function of time after addition of the enzyme. The remaining traces correspond to 
controls where enzyme (black trace), NADH (red) or FAD (blue) were omitted. The 
full value of kcat is not realized in the absence of exogenous FAD. 
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3.8. HpxO M208I. 
This residue is more remote from the flavin and urate molecules than the other amino 
acids mutated in the present study (Figure 3.12). It is also located on the β-sheet 
region of the “monooxygenase domain”, suggesting that it may have a role in substrate 
recognition or in mediating the conformational changes induced by substrate binding. 
The mutant showed impaired catalytic activity compared with wtHpxO. The most 
striking feature was change in the dependence of the steady-state rate on the NADH 
concentration (Figure 3.13). This dependence was linear up to 1 mM and could not be 
saturated even at 2 mM NADH, suggesting that the KM value for NADH is > 1 mM. 
The enzyme still exhibited saturation kinetics with urate, with a Vmax/Eo value of 0.65 
± 0.03 s−1 at 1 mM NADH, a reduction of two orders of magnitude over wtHpxO. 
However, the KM value for urate was essentially unchanged, at 35 ± 7 μM. 
Figure 3.12. Position of the HpxO M208I residue. 
 
These results implicate the M208I residue as being important for the conformational 
changes which result in flavin reduction during the catalytic cycle, and are consistent 
with the observations made for related FAD-dependent monooxygenases that residues 
remote from the active site participate in a network of amino acid side chains which 
facilitates global conformational changes of relevance to catalysis. 
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Figure 3.13. Steady-state kinetics of urate oxidation catalyzed by HpxO M208I. 
Assays were carried out in 0.1 M potassium phosphate buffer, pH 8.0, in the presence 
of 0.01 mM FAD. The enzyme concentration was 900 nM. a) Dependence of steady-
state rate on NADH concentration in the presence of 1.0 mM urate. The KM for NADH 
was > 1.0 mM; b) Dependence of the steady-state rate on urate concentration in the 
presence of 1.0 mM NADH. The Vmax/Eo value for urate was 0.65 ± 0.03 s−1. The KM 
for urate was 35 ± 7 μM. 
 
 
3.9. HpxO Y176F. 
This residue forms hydrogen bonds with the side chain carboxylate group of D293 and 
may thus be part of an extended hydrogen bonding network involving that residue and 
R204 (Figure 3.14). The Y176 residue is also within hydrogen bonding distance of an 
ordered water molecule which in turn is hydrogen bonded to the N8 atom of the uric 
acid. This residue may thus be important both for substrate binding and for proton 
transfer steps in the oxygenation reaction. 
Kinetic studies on HpxO Y176F were hampered by its extremely low activity. The 
protein appears to exhibit a very low affinity for FAD. The enzyme co-purifies with 
almost no detectable FAD. 
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Figure 3.14. Position of the HpxO Y176 residue and its potential hydrogen bonding 
interactions with D293 and an ordered water molecule (pink dot). 
 
 
Addition of a 50-fold molar excess of exogenous flavin (0.01 mM) resulted in only a 
small increase (≤ 25%) in enzymatic turnover, suggesting that this mutant, like many 
of the others, is impaired in flavin binding. The V/Eo value at 1 mM NADH and urate, 
and 0.01 mM FAD, was ~0.1 s−1. 
 
3.10. HpxO S43A  
This residue is located close to the pyrimidyl portion of the FAD isoalloxazine ring 
and can form two hydrogen bonding interactions with the cofactor (Figure 3.15). S43 
may thus be important for flavin binding and for determining the “out” or “in” 
position of the flavin during the HpxO catalytic cycle. 
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Consistent with this assignment of an important role for S43, the S43A mutant of 
HpxO was considerably less active than any of the other mutants studied here, with the 
exception of of R204K and Y176F. This was characterized by an increase in the KM 
Figure 3.15. Position of HpxO S43 residue. 
Figure 3.16. Steady-state kinetics of urate oxidation catalyzed by HpxO S43A. Assays 
were carried out in 0.1 M potassium phosphate buffer, pH 8.0, in the presence of 0.01 
mM FAD. The enzyme concentration was 700 nM. a) Dependence of steady-state rate 
on NADH concentration in the presence of 1.0 mM urate. The KM for NADH was 
estimated at 0.92 ± 0.2 mM; b) Dependence of the steady-state rate on urate 
concentration in the presence of 1.0 mM NADH. The Vmax/Eo value was 0.066 ± 0.002 
s−1. The KM for urate was 33 ± 5 μM.  
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for NADH (to  ~0.9 mM) and an order of magnitude decrease in the turnover number. 
The KM for urate was similar to that of wtHpxO (Figure 3.16).  
 
3.11. Conclusion. 
The steady-state kinetic parameters for seven active site mutants of HpxO were 
determined. All of the mutants showed impaired catalytic activity. The R204 residue is 
critically important for catalysis of the oxygenation reaction, most likely due both to 
stabilization of the transition state for oxygenation, by hydrogen bonding and 
electrostatic interactions with the N1-C2-O2′ region of the HpxO-bound uric acid. 
Additionaly, the R204Q mutant could catalyze the steady-state oxidation of NADH in 
a manner that was essentially independent of the presence of urate. This uncoupled 
reaction appears to implicate the R204 residue as being important for gating the 
conformational changes in the enzyme that follow substrate binding and allow flavin 
motion and reduction by NAD(P)H. The HpxO M208I mutant showed a dramatically 
altered KM for NADH, which highlights the importance of residues remote from the 
active site, and by implication the importance of protein dynamics, for catalysis in 
HpxO and related flavin monooxygenases. 
 
3.12. Experimental. 
3.12.1. Protein production. 
Overexpression vectors for each of the HpxO mutants were prepared by single-point 
mutagenesis of the vector encoding wtHpxO by Cynthia Kinsland (Protein Production 
Facility, Cornell University). The resulting plasmids were used for heterologous 
overexpression of the various mutants in E. coli using standard procedures. The 
proteins were stored at −80 °C in 0.1 M potassium phosphate buffer, pH 8.0, until use. 
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3.12.2. Steady-state kinetic assays. 
Assays were carried out at 25 ± 1 °C in 0.1 M potassium phosphate, pH 8.0. NADH 
(10 mM), uric acid (2 mM), and FAD (1 mM) stock solutions were prepared freshly in 
this buffer on the day of the assay. Absorbance measurements were recorded on a 
Cary 300 Bio UV-Vis spectrophotometer (Varian). For analysis of NADH oxidation, 
an extinction coefficient of 0.745 mM−1 cm−1 at 385 nm was used. Protein 
concentrations were determined by the Bradford method (7). We previously showed 
that the concentrations of wild-type HpxO could be determined reliably by this 
method. For purposes of calculation of V/Eo, the active protein concentration was 
assumed to be equal to the total protein concentration in the presence of 0.01 mM 
FAD. 
In assays where NADH concentration was varied, the uric acid concentration was 
typically fixed at 1 mM. Where the uric acid concentration was varied, the NADH 
concentration was fixed at 1 or 1.5 mM. In some cases as noted in the text, these 
NADH concentrations were less than saturating, but were the highest concentration of 
NADH which gave a Beer-Lambert response under the assay conditions. Calibration 
experiments indicated that this introduced an error of no more than 25% into the 
kinetic constants determined under these circumstances (data not shown). 
In a typical experiment, enzyme (100–900 nM final concentration), uric acid (0–1 
mM) and FAD (0.01 mM) were pre-incubated in 0.1 M potassium phosphate buffer, 
then added to an appropriate volume of NADH (0 – 2 mM) to initiate the reaction. 
To minimize mixing effects, all other components of the HpxO reaction were typically 
added to the appropriate volume of NADH stock solution in order to initiate the 
reaction. The reaction mixtures were then manually mixed prior to observing the 
absorbance change at 385 nm as described above. The initial mixing step resulted in a 
delay of 12 ± 3 s between initiation of the reaction and the acquisition of the first 
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absorbance data point. The time domain for the absorbance data was chosen to 
produce the best linear fit to the initial change in 385 nm absorbance. In the cases of 
some of the mutants there was an initial rapid decrease in absorbance (t1/2 ~ 20 s) 
which showed pronounced curvature and was followed by a longer linear phase. This 
initial data was poorly described by a “burst” type model and was attributed to mixing 
effects and omitted from the linear fit. 
The absorbance data were analyzed by fitting the linear portions of the initial 
absorbance decay by linear least-squares regression to determine the rates of change of 
absorbance at 385 nm as a function of initial substrate concentration. These rates were 
converted to rates of change of NADH concentration and plotted as a function of 
[NADH]o. The resulting data were fit by nonlinear regression to the Michaelis-Menten 
equation using the Grafit 5.0 software package (Erithacus Software, Surrey, UK). 
Kinetic traces presented in the Figures are typically representative traces from a single 
experiment. The kinetic constants were determined on the basis of at least two 
independent experiments. The standard errors reported in the text are the standard 
errors to the linear or nonlinear fits. 
 
3.12.3. HPLC analysis of the products of the HpxO R204K/Q mutants. 
All reactions were assayed by reverse-phase HPLC on an Agilent 1100 HPLC system 
equipped with a quaternary pump and a 1.0 mL sample loop. The system also had a 
diode array UV-Vis detector (190 – 640 nm) and a fluorescence detector. The 
stationary phase was a Supelcosil LC-18-T column (15 cm × 4.6 mm, 3 μm particles), 
maintained at room temperature (21 ± 1 °C). At the end of the incubation period for 
the enzymatic reaction, the protein was removed by centrifugal ultrafiltration of the 
reaction mixture (10 kDa MWCO membrane). Aliquots of 0.02 – 0.05 mL of the 
filtrate were then removed and analyzed for urate and allantoin. The LC eluent 
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consisted of a gradient of methanol in 10 mM potassium phosphate buffer, pH 6.6. In 
the analytical method the percentages P and M of phosphate buffer and methanol 
(balance water) at time t varied according to the following scheme: {t,P,M}: 
{0,100,0},{4,90,0},{9,60,15},{14,10,65},{16,100,0},{21,100,0}. 
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CHAPTER 4 
Identification and initial characterization of a biosynthetic pathway for 
bacimethrin in Clostridium botulinum A ATCC 19397. 
 
4.1. Introduction 
Bacimethrin (4.1, Figure 4.1) was first isolated from strains of Bacillus megaterium in 
the early 1960s (1). The compound was observed to exhibit antibiotic activity against 
a variety of yeast species and several bacteria. The bacimethrin antibiotic activity was 
found to be attenuated in the presence of thiamin pyrophosphate 4.9 (vitamin B1) and 
pyridoxine (vitamin B6). The first chemical synthesis of the compound was reported in 
1962 (2). The efficacy of the compound as an antibiotic in a mouse model was then 
assessed, and was found to be slight to moderate against a variety of clinically-
relevant pathophysiological states (3). The results of these studies suggested that 
bacimethrin may have limited utility as an antibiotic. 
Two decades later, the production of bacimethrin was also observed in Streptomyces 
albus (4). A further synthesis was described and data was presented which suggested 
that bacimethrin might inhibit the phosphorylation of its close structural analogue 
HMP-OH 4.2, a key pyrimidine intermediate in thiamin biosynthesis. A third chemical 
synthesis of bacimethrin was reported subsequently (5). 
Figure 4.1. Bacimethrin 4.1 and HMP-OH 4.2, and their enzymatic conversion to 
methoxythiamin pyrophosphate 4.8 and thiamin pyrophosphate 4.9. 
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Later studies assessed in greater detail the molecular basis for the effects of 
bacimethrin on bacterial growth. Zilles et al. reported that the bacteriostatic effects of 
bacimethrin had their origin in modulation of thiamin biosynthesis (6). In particular, 
Salmonella enterica serovar Typhimurium mutants that exhibited increased expression 
of the thi operon, which codes for the thiamin biosynthetic genes, or mutants with 
defects in thiD, the gene product of which (phosphomethylpyrimidine kinase) 
phosphorylates HMP-OH 4.2 and HMP-P 4.4, showed increased resistance to 
bacimethrin. This led to the proposal that bacimethrin could either inhibit thiamin 
biosynthesis in competition with HMP-OH, by binding to thiamin biosynthetic 
enzymes which process HMP-OH or its downstream products. An alternative 
hypothesis postulated that bacimethrin could enter into thiamin biosynthesis, resulting 
in production of methoxythiamin pyrophosphate (MeOThDP) 4.8, which was 
proposed in this model to be the true bacteriostatic agent. Subsequent studies showed 
that bacimethrin is enzymatically converted to methoxythiamin pyrophosphate six-
fold faster in vitro than HMP-OH is converted to thiamin pyrophosphate 4.9 (7). 
Bacimethrin pyrophosphate is a substrate (8) for thiamin phosphate synthase (ThiE, 
Figure 4.1). Later pre-steady-state kinetic studies on ThiE showed that the key ThiE 
intermediate, a pyrimidine-derived carbocation, forms 16 times faster from 
bacimethrin pyrophosphate than from HMP-PP at the ThiE active site (9). Cell-based 
studies also concluded that the observed effects of bacimethrin on bacterial growth 
were due to inhibition by MeOThDP of metabolic pathways dependent on the thiamin-
dependent enzymes α-ketoglutarate dehydrogenase, transketolase, and deoxy-D-
xylulose-5-phosphate synthase (7). 
Bacimethrin was later used in a genetic screen to identify thiamin metabolic genes 
(10). The screen identified genes which conferred resistance to bacimethrin, including 
five genes of previously unknown function. Of these five, two gene products (YmfB 
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and Cof) catalyzed the hydrolysis of HMP-PP to HMP-P. YmfB was also shown to 
catalyze conversion of thiamin pyrophosphate to thiamin phosphate.  
One curious conclusion from the cell-based studies (7) on bacimethrin/MeOThDP 
toxicity was the following. While the effects of bacimethrin treatment on sensitive 
bacteria were interpreted as arising from blockade of metabolic pathways dependent 
on thiamin pyrophosphate-utilizing enzymes, the effects of bacimethrin could be 
reversed by providing the bacteria with any one of the nutrient sets for which 
organisms bearing mutations in the genes coding for the thiamin-dependent enzymes 
in question were auxotrophic. The combination of all the sets of nutrients was not 
required to antagonize the effects of bacimethrin. It was unclear how this effect was 
produced. 
The present work had two principal aims. The first was to characterize a putative 
biosynthetic operon for bacimethrin in Clostridium botulinum. The second was to 
further understand the molecular basis for the bacteriostatic effects of bacimethrin.  
 
4.2. Identification of a gene cluster responsible for bacimethrin production in 
Clostridium botulinum A ATCC 19379. 
Inspection of the sequenced genome of C. botulinum reveals a gene cluster potentially 
involved in bacimethrin biosynthesis. We had previously hypothesized that 
bacimethrin could be produced from cytosine in two steps (Figure 4.2).  This could  
 
Figure 4.2. Proposed biosynthesis of bacimethrin 4.1 from cytosine 4.10. 
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Figure 4.3. Genetic organization and homology-based annotated enzymatic activities 
for the bacimethrin biosynthetic cluster in Clostridium botulinum A ATCC 19397.  
CH2-THF is 5,10-methylenetetrahydrofolate 4.16; SAM is S-adenosyl-L-methionine 
4.17; ABC is “ATP-binding cassette“. 
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occur by hydroxymethylation of the 5-position of cytosine using a formaldehyde 
equivalent, followed by methylation at the O-2′ position of the pyrimidine. The order 
of these steps could also be reversed in the biosynthetic pathway. We found that the C. 
botulinum A ATCC 19397 genome contains a gene cluster (Figure 4.3) with genes 
annotated as thymidylate synthase, a putative glycosyltransferase, a SAM-dependent 
methyltransferase, and a phosphomethylpyrimidine kinase (thiD-2). Additionally, the 
cluster contained genes proposed to code for an ABC transporter and a putative 
thiaminase I. 
Thymidylate synthase is closely related to cytidylate hydroxymethylase; both enzymes 
catalyze a methylenetetrahydrofolate-dependent hydroxymethylation at the 5-position 
of pyrimidine nucleotides (dUMP or CMP 4.12 respectively) (11,12). The C. 
botulinum enzyme in the putative bacimethrin biosynthetic cluster also showed high 
sequence similarity with the MilA enzyme from Streptoverticillium rimofaciens 
ZJU5119, which catalyzes the same reaction in the biosynthesis of the peptidyl 
nucleoside antibiotic mildiomycin (13). The MilA enzyme was shown to exhibit 
specificity for CMP as its nucleotide substrate. We thus proposed that bacimethrin 
could be synthesized from CMP 4.12 in C. botulinum, rather than directly from 
cytosine. We assigned the name bcmA to the C. botulinum gene. 
A second putative enzyme-encoding gene in the cluster, which we designated bcmB, 
was annotated as a hypothetical protein possessing a conserved domain homologous to 
the nucleoside 2-deoxyribosyltransferase enzyme family (14). Moreover, this enzyme 
also showed considerable sequence homology with the second enzyme of the 
mildiomycin biosynthetic pathway, MilB. The MilB enzyme catalyzes the conversion 
of 5-hydroxymethylcytidine monophosphate 4.13 to 5-hydroxymethylcytosine 4.14. 
We thus proposed this step to also be the second step in bacimethrin biosynthesis. 
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The third enzyme in the cluster was annotated as putative methyltransferase and 
contained a conserved domain proposed to bind the methyl donor S-
adenosylmethionine (15). We thus proposed that this enzyme, which we designated as 
BcmC, could catalyze transfer of a methyl group from S-adenosylmethionine (SAM) 
to the O-2 position of 5-hydroxymethylcytosine, producing bacimethrin 4.1. 
The fourth enzyme in the putative biosynthetic cluster, which we designated BcmD, 
was annotated as a kinase with homology to ThiD, the kinase responsible for 
phosphorylation of HMP-OH 4.2 and HMP-P 4.4 in the late biosynthetic steps of 
thiamin phosphate biosynthesis. Consequently we proposed that C. botulinum could 
produce bacimethrin pyrophosphate, which could be endogenously coupled to thiazole 
phosphate 4.7 by the ThiE enzyme (thiamin phosphate synthase), producing 
methoxythiamin pyrophosphate. The genome of C. botulinum A ATCC 19397 
contains a gene (CLB_0490) which is proposed to encode the ThiE protein.  
The bacimethrin biosynthetic cluster also appears to contain the components of an 
ABC transporter. The presence of such transporters in the biosynthetic gene clusters of 
antibiotics is well-precedented, and is thought to be involved in export of the 
biosynthesized toxin (16). In the present context, the role of such an ABC transporter 
could be to export bacimethrin, or its phosphorylated derivatives, or methoxythiamin 
itself, constituting a detoxification mechanism for the thiamin analogue in the 
producing organism. 
The presence of the thiaminase I in the cluster could also aid in this detoxification 
process. Thiaminase I catalyzes the substitution of the thiazolium portion of thiamin 
(and its phosphorylated analogues) with a variety of nucleophiles (17), but in contrast 
to thiaminase II (18), the nucleophilic substrate cannot be water. Thus thiaminase I 
does not catalyze formation of HMP-OH from thiamin. In the case of thiaminase II, 
water is the only nucleophilic substrate. Thiaminase II has been implicated in salvage 
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of HMP-OH from thiamin derivatives in which the thiazolium portion of the cofactor 
has been degraded (19,20). The function of thiaminase I has remained unclear to date. 
 
4.3. Functional characterization of the bcm cluster. 
The bcmA, bcmB, bcmC and bcmD genes were separately cloned into vectors 
encoding an N-terminal 6×His tag and heterologously overexpressed in E. coli using 
standard procedures, by Lisa Cooper (Texas A&M University). The resulting proteins 
were purified by Ni2+-affinity chromatography using standard conditions. We then 
examined whether the enzymes exhibited the proposed catalytic activities in vitro. 
 
4.3.1. BcmA and BcmB. 
4.3.1.1. Activity. 
Treatment of cytidine monophosphate 4.12 with BcmA and either commercially-
available 5,10-methylenetetrahydrofolate 4.16, or the compound produced in situ 
(Figure 4.4) from the reaction of formaldehyde with an excess of tetrahydrofolic acid 
4.15 (21), resulted in conversion of the CMP to a less polar product (Figure 4.5d).  
Figure 4.4. Reactions catalyzed by BcmA and BcmB. 
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Figure 4.5. Analysis of activity of BcmA and BcmB. CMP 4.12 (RT 2.0 minutes) was 
treated with BcmA or a combination of BcmA and BcmB in the presence of 5,10-
methylenetetrahydrofolate 4.16. The reactions were analyzed by reverse-phase HPLC 
after a 3 h incubation. Chromatograms were detected at 270 nm. a) HPLC 
chromatogram of the BcmAB reaction mixture; b) Full reaction spiked with authentic 
5-hmC; c) control reaction omitting CMP, and showing the presence of a CH2THF-
derived compound which co-elutes with 5-hmC at 3.1 minutes; d) control reaction 
omitting BcmB, showing accumulation of the BcmA product (“PBcmA”, 4.35 
minutes) and lack of accumulation of 5-hmC; e) control reaction omitting BcmA, 
showing lack of accumulation of the BcmA product and 5-hmC; f) control reaction 
omitting 5,10-methylenetetrahydrofolate; g) overlay of expanded chromatograms in 
the 5-hmC region: red - full reaction, blue - full reaction spiked with 5-hmC, green – 
5-hmC standard at the same concentration used to spike sample (g); h) relative 
integration values for the 5-hmC region (3.0–3.5 minutes) in chromatograms (a)-(f), in 
red, and the sum of the value for the full reaction (a) and the value contributed only by 
the added standard 5-hmC, in green. 
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The UV absorbance spectrum of this product suggested it was a cytosine derivative. 
The product was also sensitive to treatment with alkaline phosphatase, indicating that 
it was phosphorylated. This product was not formed in the absence of BcmA, CMP, or 
methylenetetrahydrofolate, and was proposed to be 5-hydroxymethyl-CMP 4.13. 
Treatment of this product with BcmB resulted in its consumption and formation of 5-
hydroxymethylcytosine 4.14. This latter assignment was confirmed by reverse-phase 
HPLC, where the BcmB product co-eluted with an authentic standard of 5-
hydroxymethylcytosine (Figure 4.5a, 4.5b). Where BcmA and BcmB were incubated 
with CMP and the methylenetetrahydrofolate preparation, the BcmA product did not 
accumulate to the extent observed when only BcmA was present, suggesting that 
BcmB can efficiently catalyze the reaction of the BcmA product. No product was 
observed when BcmA, or both BcmA and BcmB were incubated with dCMP. This 
data is consistent with the proposed activities for BcmA and BcmB, particularly when 
considered along with the sequence homology of BcmA and BcmB to the MilA and 
MilB enzymes which are known to catalyze the sequential formation of 4.13 and 4.14, 
respectively. 
 
4.3.1.2. Steady-state kinetic parameters for BcmA. 
The steady-state hydroxymethylation of CMP catalyzed by BcmA was monitored by 
following the decrease in absorbance at 290 nm, which results from the conversion of 
5,10-methylenetetrahydrofolate to tetrahydrofolate. This method has been used 
previously in kinetic studies on the formation of 5,10-methylenetetrahydrofolate (21). 
The enzyme exhibited saturation kinetics with both CMP and 5,10-
methylenetetrahydrofolate. The Km for CMP was estimated at 12 μM (Figure 4.6), 
while that for 5,10-methylenetetrahydrofolate was ≤ 2 μM. A more sensitive assay 
will be required to accurately determine the Km value for the 
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methylenetetrahydrofolate. The kcat value was estimated at ~0.02 s−1, using a value of 
3.0 mM−1 cm−1 for Δε290 between methylenetetrahydrofolate and tetrahydrofolate (22). 
Under the assay conditions there was no evidence that the hydroxymethylation 
reaction produced a significant change in absorbance at 290 nm for the cytidine 
chromophore. 
Figure 4.6. Representative Michaelis-Menten plot for the BcmA-catalyzed reaction of 
CMP with 5,10-methylenetetrahydrofolate. The values of Km,CMP and kcat were 
estimated at 12 μM and 0.02 s−1, respectively. The Km value for 
methylenetetrahydrofolate was ≤ 2 μM. The rates were determined by following the 
change in absorbance at 290 nm, which reports on conversion of 
methylenetetrahydrofolate to tetrahydrofolate. 
 
4.3.2. BcmC 
To investigate whether BcmC could catalyze the formation of bacimethrin 4.1 from 5-
hydroxymethylcytosine 4.14, we incubated substrate and enzyme in the presence of S-
adenosyl-L-methionine iodide 4.17. This resulted in formation of bacimethrin and S-
adenosylhomocysteine 4.18 (Figures 4.7, 4.8). Initial assignment of the products was 
made on the basis of co-elution with authentic standards. Bacimethrin was not 
detected in controls where enzyme, CMP, or SAM were omitted. Formation of 
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bacimethrin was also confirmed by positive-mode ESI-TOF mass spectrometry 
(Figure 4.9). An ion was detected in the mass spectrum of the reaction mixture at 
156.078 m/z, which was not present in a control where enzyme was absent. The mass-
to-charge ratio of this ion agrees with the calculated value for the bacimethrin [M+H]+ 
ion within 2.6 ppm. Fragmentation of this ion by collisionally-induced dissociation 
resulted in the accumulation of daughter ions at 138 m/z (loss of water) and 81 m/z, 
consistent with the bacimethrin structure and the fragmentation pattern known for 
HMP-OH (23). 
 
4.3.3. BcmD 
This enzyme is annotated as thiD-2 in the C. botulinum genome, and thus is predicted 
to catalyze formation of, sequentially, bacimethrin phosphate 4.3 and bacimethrin 
pyrophosphate 4.5. Incubation of bacimethrin with BcmD, ATP and MgCl2 resulted in 
consumption of ATP and bacimethrin (Figure 4.10). Controls where ATP or the 
enzyme were omitted showed no reaction of the bacimethrin. A more polar product 
was observed in the reverse-phase HPLC chromatogram of the reaction mixture which 
was consistent with formation of bacimethrin phosphate. Efforts to confirm the 
identity of this product are ongoing. 
 
4.3.4. 2′-Methoxythiamin is not a substrate for the C. botulinum thiaminase I. 
2′-Methoxythiamin 4.19 was treated with the thiaminase I found in the bcm cluster 
(CbtThia-I) in the presence of β-mercaptoethanol, which acts as a nucleophilic 
substrate (Figure 4.11). Under conditions where this enzyme efficiently cleaved 
thiamin 4.20, no reaction of methoxythiamin was observed. This result is intriguing in 
that it suggests the thiaminase may have a function other than detoxification of the 
methoxythiamin derived from bacimethrin. Further investigation of this is underway. 
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 Figure 4.7. Activity of BcmC. 5-Hydroxymethylcytosine (hmC 4.14, 0.2 mM) was 
treated with S-adenosylmethionine iodide (SAM 4.17, 2 mM) in the presence of 
BcmC (5 μM) for 2.5 h in 50 mM HEPES, pH 7.5 at 25 ± 1 °C. Top – control lacking 
enzyme; Bottom – full reaction. Inset: expanded section of the chromatogram in which 
the bacimethrin (BCM) and S-adenosylhomocysteine (SAH) products eluted, overlaid 
with chromatograms (in color) produced from analysis of authentic standards of these 
compounds. 
Figure 4.8. Reaction catalyzed by BcmC. 
85 
 Figure 4.9. ESI-TOF MS analysis of bacimethrin produced by BcmC. The enzyme 
(2.75 μM) was incubated with 5-hydroxymethylcytosine (0.25 mM) and S-adenosyl-L-
methionine iodide (0.3 mM) in 25 mM ammonium acetate, pH 6.2, for 3.5 h. The 
reaction mixture was then analyzed by ESI-TOF +MS after removal of the enzyme by 
centrifugal ultrafiltration. a) ESI-TOF +MS of a control reaction lacking BcmC; b) 
MS of reaction mixture showing ion at 156.1 m/z; c) Exact mass determination of 
bacimethrin-derived ion (theoretical [M+H]+ 156.0773, accuracy 2.6 ppm); d) ESI-
MS/MS spectrum of BcmC product showing fragmentation expected for bacimethrin. 
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Figure 4.10. In vitro activity of BcmD. Bacimethrin (BCM, 0.48 mM) was incubated 
with ATP (10 mM) and MgCl2 (5 mM) in the presence of BcmD (0.125 mM), in 50 
mM HEPES, pH 7.5 for 2.5 h at 25 ± 1 °C. The reaction mixture was then diluted with 
water to 0.3 mL and the protein was removed by centrifugal ultrafiltration (3 kDa 
MWCO membrane). 0.05 mL aliquots of the filtrate were analyzed by reverse-phase 
HPLC. Top – control omitting BcmD; Middle – control omitting ATP; Bottom – full 
reaction mixture indicating ATP- and BcmD-dependent consumption of bacimethrin. 
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Figure 4.11. Activity of thiaminase I from C. botulinum A ATCC19397 (CbtThia-I). a) 
Reaction catalyzed by thiaminase I, which converts thiamin 4.20 or its phosphorylated 
derivatives to thiazole 4.22 (or phosphorylated derivatives) and a pyrimidyl product 
derivatized with the nucleophilic substrate, which cannot be water; b) Reaction of 
thiamin with CbtThia-I in the presence of β-mercaptoethanol, monitored by 1H NMR 
spectroscopy. The resonance marked in red is due to the thiazolium C2-proton (δH 
9.38 ppm), which is converted to the resonance marked in blue (8.73 ppm) by the 
enzymatic activity. The small amount of thiazole present at the commencement of the 
NMR experiment is due to the interval (~45 s) between addition of the β-
mercaptoethanol and acquisition of the first spectrum. Controls lacking enzyme also 
lack this resonance (not shown); c) Incubation of methoxythiamin 4.19 under 
conditions identical to those for the reaction of thiamin shows no accumulation of 
thiazole. 
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4.4. Discussion. 
The results described here constitute the identification of the biosynthetic pathway for 
bacimethrin in C. botulinum A ATCC 19397. The molecule can be produced from 
CMP in three enzymatic steps using well-precedented chemical transformations. 
Additionally, the presence of the thiaminase I protein in the biosynthetic cluster, 
which can degrade thiamin but not methoxythiamin, leads to several intriguing 
questions relating to the mechanism of toxicity of bacimethrin. The first of these 
questions is whether thiaminase I can potentiate the bacteriostatic activity of 
bacimethrin in vivo. The thiaminase I protein was previously shown to be an 
extracellular enzyme in the cases of a variety of organisms, including Bacillus 
thiaminolyticus. The C. botulinum thiaminase I gene also encodes the N-terminal 
signal peptide which targets the protein for export (24). If C. botulinum exports both 
bacimethrin and thiaminase I, are these employed synergistically to both deplete 
thiamin available to competing microorganisms, and simultaneously provide the 
competitors a structural analogue of the cofactor which inhibits their metabolism? 
A second, related question is whether C. botulinum and other organisms can in fact 
utilize methoxythiamin pyrophosphate as a cofactor, instead of thiamin 
pyrophosphate. To our knowledge, no detailed biochemical studies on isolated 
thiamin-dependent metabolic enzymes from Clostridium have been carried out. This 
latter issue is probably due to the practical difficulties associated with studying the 
highly pathogenic C. botulinum. Ideally, another bacimethrin- and thiaminase I-
producing organism which is non-pathogenic would be an invaluable model with 
which to address the questions posed above. BLAST analysis starting from the 
thiaminase I protein reveals that the bacimethrin biosynthetic cluster containing the 
thiaminase I-coding gene is present in a number of the Clostridia and also is likely to 
be present in several strains of Burkholderia pseudomallei, as well as in Burkholderia 
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thailandensis E624. Identification of organisms which produce both bacimethrin and 
the thiaminase protein, but are relatively non-pathogenic, will be important for further 
in vivo characterization of the biological mechanisms underlying bacimethrin toxicity.  
Further analysis of the genome sequence of C. botulinum A ATCC19397 reveals an 
idiosyncratic genotype with respect to thiamin biosynthesis. This was previously 
identified based on comparative genomic analysis (25). The organism lacks most of 
the genes for biosynthesis of the thiamin thiazole, including the thiazole synthase 
(thiG, 26) and the genes (thiS, thiF) responsible for delivery of sulfur to the thiazole 
during the thiazole synthase reaction (27). The organism also does not appear to 
possess a gene encoding a protein with homology to THI4p, the single eukaryotic 
thiazole biosynthetic enzyme (28). However, the C. botulinum genome contains the 
thiM gene, proposed to encode thiazole kinase. This gene is required to produce a 
thiazole substrate which can efficiently undergo the thiamin phosphate synthase 
(ThiE) reaction. The organism is thus either incapable of producing the thiazole 
moiety of thiamin by itself, or does so by an as-yet uncharacterized pathway. This 
genotype appears to be conserved among members of the Clostridia which possess the 
thiaminase I gene and the bacimethrin biosynthetic pathway. 
C. botulinum also possesses the thiC gene, which is responsible for HMP biosynthesis 
in a variety of organisms (29). However, the C. botulinum ThiC appears to contain a 
mutation in the important conserved region responsible for ligation of the [4Fe-4S] 
cluster required for the enzyme’s activity. This involves deletion of a conserved 
proline residue which converts the archetypal HMP-P synthase (ThiC) CX2CX4C 
motif to a CX2CX3C sequence. This differs also from the conserved CX3CX2C motif 
observed in other members of the radical SAM superfamily (30). It is consequently 
unclear at the present time whether CbtThiC is an active HMP-P synthase. 
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The organism’s genotype thus suggests that C. botulinum A ATCC 19397 could 
produce thiamin pyrophosphate if it were supplied exogenous thiazole and if the ThiC 
protein were active. The available data also suggest that the organism could produce 
methoxythiamin from bacimethrin under the same conditions. One of the most 
fascinating questions remaining to be answered is whether the thiaminase I enzyme, 
which obligatorily produces thiazole from thiamin, is exported by C. botulinum (and 
other organisms with similar genotypes) to simultaneously destroy thiamin available 
to competing microorganisms and to produce thiazole which can be scavenged by the 
thiaminase-producing bacterium for biosynthesis of endogenous (methoxy)thiamin for 
 Figure 4.12. Proposed roles for thiaminase I, bacimethrin and methoxythiamin. 
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use in its metabolism (Figure 4.12). If this is the case, the function for thiaminase I 
from C. botulinum as a combined thiazole scavenger and potentiator of the toxicity of 
bacimethrin could be assigned. Investigation of these questions is underway presently. 
 
4.5. Experimental 
Protein concentrations were determined by the Bradford method (31). 
 
4.5.1. Analytical HPLC method 
All reactions were assayed by reverse-phase HPLC on an Agilent 1200 HPLC system 
equipped with a quaternary pump, and thermostatted autosampler (14 °C) with a 0.1 
mL sample loop. The system also had a diode array UV-Vis detector (80 Hz full 
spectral sampling, 190 – 640 nm) and a fluorescence detector. The stationary phase 
was a Supelcosil LC-18-T column (15 cm × 4.6 mm, 3 μm particles), maintained at 26 
°C. The LC eluent consisted of a gradient of methanol in 10 mM potassium phosphate 
buffer, pH 6.6. In the analytical method the percentages P and M of phosphate buffer 
and methanol (balance water) at time t varied according to the following scheme: 
{t,P,M}:{0,100,0},{5,90,0},{11,60,15},{23.5,10,65},{25,100,0},{30,100,0}. 
  
4.5.2. In vitro activity of BcmA and BcmB 
CMP (0.125 mM) and (6R,S)-5,10-methylenetetrahydrofolate (0.125 mM) were 
incubated with  BcmA (7 μM) in 0.1 M potassium phosphate buffer, pH 8.0, 
containing 0.15 M potassium chloride and β-mercaptoethanol (10 mM). Reactions 
were incubated in darkness for 3 h at 25 ± 1 °C. Control reactions identical to the 
above but lacking, variously, CMP, methylenetetrahydrofolate, and BcmA were also 
prepared. The protein was then removed by centrifugal ultrafiltration through a 3 kDa 
MWCO membrane (Microcon, Millipore) and 50 μL aliquots of the filtrate were 
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analyzed by reverse-phase HPLC. Chromatograms were detected using the absorbance 
at 254 nm. UV-Vis spectra of substrate and product peaks were also collected. 
For analysis of the BcmB activity, a sample identical to the above was prepared but 
which included BcmB (8 μM). 
In a separate experiment, 5,10-methylenetetrahydrofolate was also prepared in situ by 
addition of formaldehyde. (final concentration 1 mM) to a 0.5 mL solution of 
tetrahydrofolic acid (~5 mM, Sigma) in 0.1 M potassium phosphate buffer, pH 6.6. 
Aliquots (0.04 mL of this solution were then quenched into the BcmA reaction 
mixture (0.2 mL final volume). In this case the reactions were incubated overnight in 
darkness. 
 
4.5.3. In vitro activity of BcmC. 
S-Adenosyl-L-methionine (SAM, 2 mM) and 5-hydroxymethylcytosine (0.2 mM) 
were incubated with BcmC (0.01 mM) in 50 mM HEPES, pH 7.5 for 1.5 h at 25 ± 1 
°C. The reaction mixtures (0.05 mL) were then diluted to 0.3 mL with water and the 
protein was removed by centrifugal ultrafiltration (3 kDa MWCO membrane). 0.05 
mL aliquots of the filtrate were then analyzed by reverse-phase HPLC using a 
modification of the method described above, with {t,M,P}: {0,0,100}, {5,0,90}, 
{8,10,75}, {14,15,60}, {20,35,50}, {25,65,10}, {28,0,100}, {33,0,100}. 
Chromatograms were detected using the absorbance at 254 nm. UV-Vis spectra of 
substrate and product peaks were also collected. 
 
4.5.4. In vitro activity of BcmD. 
Bacimethrin (0.48 mM) was incubated with ATP (10 mM) and MgCl2 (5 mM) in the 
presence of BcmD (0.125 μM), in 50 mM HEPES, pH 7.5 for 2.5 h at 25 ± 1 °C. The 
reaction mixture was then diluted with water to 0.3 mL and the protein was removed 
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by centrifugal ultrafiltration (3 kDa MWCO membrane). 0.05 mL aliquots of the 
filtrate were analyzed by reverse-phase HPLC. 
 
4.5.5. Reaction of thiamin and methoxythiamin catalyzed by C. botulinum 
thiaminase I. 
1H NMR spectra were acquired on a Varian INOVA 500 MHz instrument equipped 
with an autoswitchable probe and a Z-axis pulsed field gradient. Methoxythiamin 4.19 
(MeOThOH) was synthesized by Ahmed Al-Harrasi, Cornell University. The 
thiaminase I enzyme was heterologously overexpressed and purified using standard 
procedures by Lisa Cooper, Texas A&M University. Thiamin (4.20, ThOH) was from 
Sigma. For assessment of the enzyme activity, the substrate (MeOThOH or ThOH 10 
mM) was treated with thiaminase I (300 nM) in a solution prepared from 0.2 mL of 
0.1 M potassium phosphate buffer, pH 8.0, 0.4 mL deuterium oxide, and 0.06 mL 1 M 
KCl. The 1H NMR spectrum of this solution was acquired and used for optimization of 
the instrument Z-shims. The HDO resonance was suppressed using a shaped excitation 
pulse generated by the Varian “Wet1d” pulse sequence. To initiate the reaction, β-
mercaptoethanol was added (2.1 μL, 50 mM) to the NMR tube and the solution was 
mixed manually and replaced in the magnet (dead time ~45 s). The 1H NMR spectrum 
of the resulting solution was then monitored over time. The data for the reaction of 
thiamin were processed by application of a 0.35 Hz exponential multiplication, and the 
data for the reaction of methoxythiamin were processed by application of a 2.2 Hz 
exponential multiplication prior to Fourier transformation. 
 
4.5.6. Identification of the BcmC product as bacimethrin by ESI mass spectrometry. 
5-Hydroxymethylcytosine (0.25 mM) and S-adenosyl-L-methionine iodide (0.3 mM) 
were incubated with BcmC (2.75 μM) in 25 mM ammonium acetate, pH 6.2, for 3.5 h. 
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The enzyme was then removed by centrifugal ultrafiltration (10 kDa MWCO 
membrane, Pall Life Sciences, Ann Arbor, Michigan), and formic acid was added to 
the filtrate (final concentration 0.1 % (v/v)). The samples were thne analyzed by ESI-
TOF +MS on an Applied Biosystems Q-STAR instrument in the Laboratory for 
Biological Mass Spectrometry, Texas A&M University. 
 
4.5.7. Steady-state kinetics of the BcmA-catalyzed hydroxymethylation of CMP. 
5,10-Methylenetetrahydrofolate was from Schircks Laboratories, Jona, Switzerland. In 
a typical assay, BcmA (760 nM) was incubated with 5,10-methylenetetrahydrofolate 
(0.05 mM) and CMP (0 – 0.2 mM) in 50 mM HEPES, pH 7.5 containing 0.15 M 
potassium chloride. The addition of potassium chloride was required to prevent 
precipitation of the enzyme. β-Mercaptoethanol was also included at 10 mM. The 
reaction was initiated by addition of the methylenetetrahydrofolate. In control 
experiments where the enzyme or CMP was omitted, the methylenetetrahydrofolate 
absorbance at 290 nm did not measurably decrease on the time scale of the experiment 
(typically 100 s).  
The value of V/Eo was estimated from the relation 
 
                   (4.1) dtE
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ε=
dAV 2
PSo
1
ΣΔ
 
where ΣΔεPS is the difference between the sums of the 290-nm extinction coefficients 
of the products and reactants. There was no evidence for changes in the absorbance 
spectrum other than those attributable to interconversion of the pterin compounds.
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 CHAPTER 5 
Summary and outlook. 
 
5.1. CysM. 
5.1.1. Summary. 
Our kinetic studies on CysM led to the conclusion that the amino acid substrate for 
this enzyme is not O-acetyl-L-serine, as had been previously thought. Instead, the 
enzyme selectively uses O-phospho-L-serine as the amino acid precursor for L-
cysteine. This had not been observed previously in bacteria, and had been observed 
only once in total, in the hyperthermophilic archaeon Aeropyrum pernix. 
This study also was the first to offer a detailed kinetic characterization of the transfer 
of sulfur from a small sulfur carrier protein to an enzyme-bound biosynthetic 
intermediate. The kinetic results complemented a crystallographic study which 
showed that the CysM active site containing the α-aminoacrylate intermediate is 
occluded from solvent in the absence of CysO, and that very specific interactions 
between CysM and CysO are required to open the small channel through which the 
sulfur atom is delivered on the flexible CysO-COSH C-terminus (1,2). Importantly, 
the kinetics show that CysO does not bind tightly to CysM, and that the sulfur delivery 
is a kinetically-controlled event, presumably involving rapid sampling of the 
CysO/CysM interface for a configuration of the two proteins that triggers 
conformational changes allowing access to the α-aminoacrylate intermediate at the 
CysM active site. This protein-mediated selectivity is exquisite, with second order rate 
constants for the CysO-COSH/CysM-aminoacrylate reaction more than two orders of 
magnitude greater than for the reaction of the CysM-bound intermediate with the 
small anion, bisulfide. 
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 Around the same time as our study was published, a second study carried out by 
Ågren et al. arrived at similar conclusions about the substrate specificity for CysM. 
They also identified the residue responsible for selectivity for O-phosphoserine as 
Arg220. Mutating this residue greatly reduces the selectivity for the amino acid 
substrate (3). 
 
5.1.2. Outlook. 
5.1.2.1. Biomedical relevance of CysM. 
The unexpected substrate specificity of CysM for O-phosphoserine may be of 
biomedical relevance. The extent of flux through the CysM-dependent cysteine 
biosynthetic pathway in M. tuberculosis as it infects humans is still unclear. While 
gene expression studies have shown that expression of CysM is upregulated under 
conditions of oxidative stress, an alternate school of thought suggests that regulation is 
not necessarily an indicator of essentiality of the gene product for survival of M. 
tuberculosis, at least during the latent stages of infection when the organisms are 
living in macrophages (4). Genes required for survival in macrophages were shown to 
frequently be constitutively expressed. Nevertheless, if a potent inhibitor of CysM 
were to be found, it could potentially be a useful therapeutic agent. High-throughput 
screening strategies with this aim could be developed. 
 
5.1.2.2. Biophysical aspects. 
The CysM/CysO-COSH system involves an interesting protein-protein interaction, 
where the selective recognition of CysO-COSH by CysM containing the α-
aminoacrylate intermediate results in a kinetically controlled atom transfer reaction 
that appears to be limited by association of the proteins. Mapping out the structural 
features of the proteins that facilitate this recognition interaction would add to our 
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 understanding of transient protein-protein interactions in general, and also in the 
particular case of the small sulfur carrier proteins. The crystallographic study carried 
out by Ågren et al. Showed that the C-terminal portion of CysM is at least partly 
responsible for determining specificity for the nucleophilic substrate (1), however 
further studies are needed to fully describe the determinants of the CysO-CysM 
interaction which result in opening of the active site to the C-terminus of CysO-
COSH. Comparative similar studies on the equivalent ThiSG complex in thiamin 
biosynthesis may aid understanding of the recognition elements and other features 
which facilitate the function of this sulfur transfer system. Kinetic studies on suitably 
chosen mutants of the proteins, and also time-resolved NMR studies, could shed 
further light on the key interactions which mediate the recognition event. 
 
5.2. HpxO. 
5.2.1. Summary. 
We confirmed the proposals, arising from two genetic studies, that the urate oxidase 
enzyme in Klebsiella pneumoniae depends on a flavin adenine dinucleotide cofactor 
for its activity. All previously-studied urate oxidase enzymes are cofactor-
independent. We showed that HpxO selectively utilizes NADH over NADPH (V/K 
ratio of ~10) and that the enzyme utilizes molecular oxygen at least an order of 
magnitude more efficiently than the cofactor-independent urate oxidase. This latter 
effect is a possible reason for the evolution of this activity in K. pneumoniae, which is 
apparently found frequently in relatively oxygen-depleted habitats, such as humans. 
We also characterized the steady-state kinetics of seven active site mutants of the 
HpxO enzyme. The choice of these mutations was determined on the basis of the X-
ray crystal structure of the protein. Most of these enzymes are highly impaired in their 
ability to oxidize uric acid. In particular, the R204Q mutant can catalyze the oxidation 
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 of NADH in a manner that is essentially independent of urate, suggesting that this 
residue may be an important component of the machinery that couples substrate 
binding to flavin motion to the “out” position, allowing for its reduction and the 
subsequent oxygenation reactions in the catalytic cycle. A hydrogen bonding network 
between a number of active site residues which may be important for substrate binding 
or proton transfer reactions during catalysis was identified from the crystallographic 
data. 
 
5.2.2. Outlook. 
5.2.2.1 Biological significance. 
The sequenced genomes of a variety of organisms which appear to contain the HpxO 
enzyme also contain a gene coding for the cofactor-independent urate oxidase. In 
some cases the two urate oxidase genes are contiguous on the chromosome of the 
organism in question, in others they both appear to be present in the purine catabolic 
cluster, and in others they are found quite removed from each other on the 
chromosome. It is this unclear whether such organisms employ one or both enzymes 
for urate oxidation at a given time, or whether they are differentially regulated or 
expressed. Genomic and proteomic profiling experiments aimed at investigating the 
regulation and expression of these genes would add to our understanding of purine 
catabolism and nitrogen assimilation in these bacteria. 
Since humans cannot assimilate nitrogen from uric acid, which is excreted, an 
inhibitor of one or both of the bacterial urate oxidase enzymes may be of clinical 
relevance. A modified version of the cofactor-independent urate oxidase is currently 
employed as a therapeutic agent for cases of gout (build-up of crystalline urate in 
human joints) which is unresponsive to conventional therapies such as xanthine 
oxidase inhibitors. However, this therapeutic strategy suffers from the production of 
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 one equivalent of hydrogen peroxide per equivalent of urate oxidized. HpxO 
administered in a similar context would not produce this hydrogen peroxide side 
product. 
 
5.2.2.2. Mechanistic studies. 
The steady-state kinetic studies on the HpxO active site mutants identified a number of 
residues which are important for catalysis. While enzymes closely related to HpxO, 
such as 4-hydroxybenzoate hydroxylase, have been intensely studied, in particular the 
role of R204 of HpxO in coupling of urate binding to flavin reduction by NADH 
merits more detailed examination. A series of pre-steady-state kinetic experiments and 
biophysical measurements aimed at determining how this residue contributes to the 
HpxO catalytic cycle will provide additional insights into the function of FAD-
dependent monooxygenases. 
 
5.3. Bacimethrin. 
5.3.1. Summary. 
We identified and characterized a biosynthetic pathway for the bacteriostatic natural 
product in Clostridium botulinum A ATCC 19397. This pathway proceeds in three 
steps from cytidine monophosphate, involving sequential hydroxymethylation of the 
5-position of the nucleotide, followed by glycosyl bond cleavage, and methylation of 
the O2′-position of the resulting 5-hydroxymethylcytosine. We also demonstrated that 
the ThiD-2 gene product in the biosynthetic cluster can catalyze the reaction of 
bacimethrin in an ATP-dependent manner, presumably producing bacimethrin 
phosphate and pyrophosphate. The thiaminase I gene product, also expressed from the 
biosynthetic cluster, efficiently cleaves thiamin but not the methoxythiamin which 
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 would be derived from bacimethrin, suggesting that the purpose of this thiaminase is 
not detoxification of endogenously-produced methoxythiamin. 
 
5.3.2. Outlook. 
5.3.2.1. The bacimethrin-derived product of C. botulinum BcmD. 
While this enzyme unambiguously catalyzes the reaction of bacimethrin in the 
presence of ATP, the product or products have not yet been isolated and fully 
characterized. This will be accomplished by a combination of LC-MS and NMR 
analyses. 
 
5.3.2.2. Substrate specificity of BcmD. 
The bcmD gene is one of two copies of the thiD gene in the C. botulinum 
chromosome. The second copy is clustered with the genes encoding thiamin phosphate 
synthase (thiE) and hydroxyethylthiazole kinase (thiM-1). Two copies of ThiD are 
found in a range of bacterial taxa including several strains of Clostridium botulinum. 
ThiD-1 is generally found clustered with genes involved in thiamin metabolism, while 
ThiD-2 is found in a variety of genetic contexts. The primary sequences of the C. 
botulinum A ATCC 19397 ThiD-1 and ThiD-2 proteins show 52% amino acid identity 
and 73% similarity. As part of an assessment of the relative utilization of 
methoxythiamin and thiamin in C. botulinum, the selectivity of the BcmD enzyme for 
bacimethrin over HMP-OH will be measured. 
 
5.3.2.3. Activity of C. botulinum ThiC. 
Sequence alignment of this protein with other ThiC enzymes showed a mutation in the 
highly-conserved sequence motif involved in ligation of the enzyme’s catalytically 
essential [4Fe–4S] cluster. It thus remains to determine whether this protein is in fact 
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 active. Synthesis of the C. botulinum thiC gene using E. coli-optimized codons and its 
subsequent overexpression, purification and characterization are currently underway. 
 
5.3.2.4. The role of methoxythiamin. 
Given that methoxythiamin is likely to be produced in vivo by Clostridium botulinum, 
what is its role in the organism? Previous studies have shown that methoxythiamin is 
bacteriostatic in Escherichia coli and other bacteria, but can methoxythiamin itself be 
used in place of thiamin in C. botulinum, making it the first naturally-occurring 
functional structural analogue of thiamin to be discovered? If this is the case, is 
methoxythiamin selectively used over thiamin by C. botulinum and other bacimethrin-
producing organisms? Owing to the technical difficulties of working with C. 
botulinum, a model organism with a similar bacimethrin biosynthetic cluster, but 
which is not highly pathogenic, would be an invaluable tool in addressing these 
questions. Efforts are presently underway to determine whether Bacillus 
thiaminolyticus, which produces thiaminase I, also contains the bacimethrin 
biosynthetic cluster. Additionally, analysis of the cofactor dependence of thiamin-
dependent enzymes from C. botulinum can partially address some of these questions in 
in vitro experiments. This can be achieved in the most practical and expedient fashion 
by synthesis of the relevant genes and their subsequent heterologous expression, 
followed by in vitro characterization of the proteins. Such studies are presently 
underway. 
 
5.3.2.5. The role of thiaminase I. 
The function of thiaminase I has remained unclear since discovery and initial 
characterization of the enzyme in the mid-20th century. Our present studies have 
shown that thiaminase I, which has been proposed by others to be an extracellular 
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 enzyme, is likely produced in concert with bacimethrin in C. botulinum. It remains to 
be determined whether thiaminase is thus a virulence factor which potentiates the 
toxicity of bacimethrin for this organism. Comparative genomic analysis does not 
indicate that bacimethrin is produced by all organisms which possess a gene encoding 
thiaminase I. However, C. botulinum appears to lack the ability to biosynthesize the 
thiazole moiety of thiamin. Thiaminase I obligatorily produces this thiazole from 
thiamin. Could the role of thiaminase I in C. botulinum be dual – to potentiate the 
toxicity of bacimethrin, and to scavenge thiazole for use by C. botulinum itself? These 
questions can best be addressed by suitable studies on a model organism, as described 
above, and efforts towards addressing these questions are underway. 
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